Condensed ring KIF18A inhibitor compound, pharmaceutical composition, and preparation method and application of fused ring KIF18A inhibitor compound and pharmaceutical composition
Patent Information
- Application Number
- CN202380035332.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-20
- Filing Date
- 2023-09-27
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-09-27
AI Technical Summary
Existing antimitotic drugs have problems with narrow therapeutic windows and collateral damage to normal cells when treating cancer. KIF18A has potential therapeutic value as a new target, but its inhibitors have not yet been effectively developed.
A class of fused ring KIF18A inhibitor compounds and pharmaceutical compositions were developed. Through specific chemical structure optimization, compounds with good KIF18A inhibitory effects and excellent physical and chemical properties were creatively obtained for the treatment of KIF18A-mediated diseases.
This compound can significantly inhibit KIF18A, reduce cancer cell migration and induce cell apoptosis, improving the safety and efficacy of treatment, especially in breast cancer and other types of cancer.
Smart Images

Figure CN119072473A_ABST
Abstract
Description
Condensed-ring KIF18A inhibitor compounds, pharmaceutical compositions, and preparation methods and applications thereof
[0001] The present invention claims:
[0002] Priority to the prior application, patent application number 202211217025.8, filed with the State Intellectual Property Office of China on September 30, 2022, entitled “Fused-ring KIF18A inhibitor compounds, pharmaceutical compositions, preparation methods, and uses thereof”;
[0003] Priority to the prior application, patent application number 202211406766.0, filed with the State Intellectual Property Office of China on November 10, 2022, entitled “Fused-ring KIF18A inhibitor compounds, pharmaceutical compositions, preparation methods, and uses thereof”;
[0004] Priority to the prior application, patent application number 202310125351.4, filed with the State Intellectual Property Office of China on February 16, 2023, entitled “Fused-ring KIF18A inhibitor compounds, pharmaceutical compositions, preparation methods, and uses thereof”;
[0005] Priority to the prior application, patent application number 202311219723.6, filed with the State Intellectual Property Office of China on September 20, 2023, entitled “Fused-ring KIF18A inhibitor compounds, pharmaceutical compositions, preparation methods and uses thereof”;
[0006] The entire contents of said prior application are incorporated herein by reference. Technical Field
[0007] The present invention belongs to the field of medicine, and specifically relates to a fused-ring KIF18A inhibitor compound, a pharmaceutical composition, and a preparation method and application thereof. Background Art
[0008] Cancer is one of the most serious diseases affecting human health, with mortality and morbidity rates often ranking among the highest among all diseases. While the continuous development and advancement of medical technology and drug research and development have greatly improved the quality of life of some patients, there are still many unmet clinical needs in the search for effective treatments or cures for different cancers. More novel targets will provide new possibilities for future cancer drug development.
[0009] Cancer cells experience unregulated cell proliferation due to damage or loss of one or more genes that regulate the cell cycle. Various kinases and kinesins have been identified that play key roles in the regulation and progression of the cell cycle and mitosis in both normally dividing cells and cancer cells.
[0010] Kinesins, also known as molecular motors, are motor proteins that use intracellular microtubules as their tracks. They convert ATP into mechanical energy and are closely involved in eukaryotic cell processes such as mitosis and meiosis, the growth and development of tissues and organs, and neuronal development and signal transduction. Kinesin members share a relatively conserved motor domain. Kinesin family members are broadly divided into three categories based on the location of the motor domain within the molecule: N-type kinesins, which have a motor domain at the amino (-NH2)-terminal region of the protein polypeptide chain; M-type kinesins, which have a motor domain in the middle region; and C-type kinesins, which have a motor domain at the carboxyl (-COOH)-terminal region.
[0011] Chromosomal instability is a hallmark of cancer and is caused by errors in chromosome segregation during mitosis. Targeting chromosomal instability is an emerging therapeutic strategy in drug development. KIF18A is a member of the N-type Kinesin-8 kinesin family and has been shown to play a role in maintaining the integrity of the bipolar spindle and promoting the viability of chromosomally unstable cancer cells. Mitosis is an effective intervention point, and many anti-mitotic drugs are used in the clinical treatment of human cancers. It is the most widely used microtubule inhibitor, which can both stabilize microtubules and prevent microtubule assembly. Current anti-mitotic drugs have the limitation of a narrow therapeutic window, and these problems need to be addressed by the development of new targets.
[0012] Although tubulin inhibitors are widely used as standard treatments for a variety of human cancer types, these drugs can cause collateral damage to normal cells, including bone marrow suppression and neurotoxicity. Because KIF18A may not be essential in normal diploid somatic cells (KIF18A knockout mice are viable but have reproductive defects, suggesting that KIF18A is not an essential gene for normal somatic cell division), targeting KIF18A may significantly reduce its toxicity, potentially extending the therapeutic safety window of tubulin-targeted drugs in the clinic.
[0013] KIF18A protein is highly expressed in a variety of tumors, including colon, breast, lung, pancreatic, prostate, bladder, head and neck, cervical, and ovarian cancers. KIF18A plays a key role in the development, progression, and metastasis of breast cancer, and its elevated expression predicts a poor prognosis. KIF18A is required for the proliferation of cells harboring chromosomal instability derived from triple-negative breast or colorectal cancers, but is not required in diploid cells. Knockout of the KIF18A gene results in infertility in male mice, but not in female mice. KIF18A mRNA expression is significantly associated with higher tumor grade and larger tumor size in breast cancer patients, and KIF18A is an independent predictor of lymph node metastasis in breast cancer, with a risk factor of 3.2. Furthermore, inhibition of KIF18A expression not only affects its critical function in mitosis but also reduces cancer cell migration by stabilizing leading-edge microtubules, ultimately leading to inactivation of the PI3K-AKT signaling pathway and induction of apoptosis.
[0014] Therefore, the development of KIF18A protein inhibitors may be a new breakthrough in cancer drugs.
[0015] Summary of the Invention
[0016] To improve the above technical problems, the present invention provides a compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug compound:
[0017] wherein A is selected from unsubstituted or optionally substituted with one, two or more R a Replaced Or fused ring group 1; the fused ring group 1 comprises two, three or four independently selected from saturated or partially unsaturated C 3-14 Carbon ring, C 6-14 aromatic ring, 5-14 membered heteroaromatic ring, 3-14 membered heterocyclic ring; each R a the same or different, independently selected from H, OH, halogen, cyano, NH2, NO2, unsubstituted or optionally substituted by one, two or more R a1 Substituted with the following groups: C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl; or, two R attached to the same ring carbon atom a Together with the carbon atoms to which it is connected, it forms a saturated or partially unsaturated C 3-14 Carbon ring; each R a1 the same or different, independently selected from H, OH, halogen, cyano, NH2, NO2, C 1-12 Alkyl, C1-12 Alkoxy, C 3-12 Cycloalkyl;
[0018] X1, X2, X3 are the same or different and are independently selected from N or CR0; R0 is selected from H, halogen, cyano, C 1-12 Alkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, cyano C 1-12 alkoxy;
[0019] B is selected from unsubstituted or optionally substituted with one, two or more R b Substituted with the following groups: C 1-12 Alkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, cyano C 1-12 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkyloxy, C 3-12 Cycloalkylthio, 3-14 membered heterocyclic group; each R b The same or different, independently selected from halogen, cyano, C 1-12 Alkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, C 1- 12 Alkoxy, halogenated C 1-12 Alkoxy, cyano C 1-12 alkoxy;
[0020] Ring G is selected from unsubstituted or optionally substituted with one, two or more R g The substituted fused ring group 2 is formed by condensing ring G1 and ring G2; ring G1 is selected from C 6-14 aromatic ring, 5-14 membered heteroaromatic ring, 3-14 membered heterocyclic ring; Ring G2 is selected from C 3-14 Carbon ring, C 6-14 Aromatic ring, 5-14 membered heteroaromatic ring, 3-14 membered heterocyclic ring; M and E are preferably attached to ring G1; each R g The same or different, independently selected from halogen, cyano, C 1-12 Alkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, cyano C 1-12 alkoxy;
[0021] E is selected from unsubstituted or optionally substituted with one, two or more R e Substituted with the following groups: -NH-S(=O)2-R e1 、-S(=O)2-NH-R e2 、-S(=O)(=NH)-R e3 、-N(R e4 )(R e5 ), 3-14 membered heterocyclic group; each R e The same or different, independently selected from OH, halogen, cyano, C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, cyano C 1-12 Alkyl, cyano C 1-12 Alkoxy, -N(R e6 )(R e7 );
[0022] R e1 、R e2 、R e3 、R e4 、R e5 、R e6 、R e7 The same or different, independently selected from H, C 1-12 Alkyl, C 1-12 Alkoxy, hydroxy C 1-12 Alkyl, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, cyano C 1-12 Alkyl, cyano C 1-12 Alkoxy, C 3-12 Cycloalkyl, 3-14 membered heterocyclic group, C 1- 12 Alkoxy-C 1-12 alkyl;
[0023] M is selected from unsubstituted or optionally substituted with one, two or more R m Substituted with the following groups: C 3-12 Cycloalkyl, C 3-12 Cycloalkenyl, 3-14 membered heterocyclic group; each R m The same or different, independently selected from halogen, cyano, C 1-12 Alkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, C 1-12 Alkoxy, cyano C 1-12 Alkoxy.
[0024] According to some embodiments, A is selected from unsubstituted or optionally substituted with one, two or more Ra Replaced Or fused ring group 1; the fused ring group 1 comprises two, three or four independently selected from saturated or partially unsaturated C 3-8 Carbon ring, C 6-10 aromatic ring, 5-10 membered heteroaromatic ring, 3-8 membered heterocyclic ring; each R a the same or different, independently selected from H, OH, halogen, cyano, NH2, NO2, C 1-6 Alkyl, C 1- 6 alkoxy, C 3-8 Cycloalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano C 1-6 Alkyl, cyano C 1-6 Alkoxy, C 3-8 Cycloalkyl-C 1-6 Alkoxy; or, two R attached to the same ring carbon atom a Together with the carbon atoms to which it is connected, it forms a saturated or partially unsaturated C 3-8 carbon ring;
[0025] According to some embodiments, A is selected from
[0026] Wherein, T is selected from CH2, CH, NH, NR a or O;
[0027] Z is selected from CH2, CH, NH, NR a or O;
[0028] X is selected from N or CH;
[0029] n is selected from 0, 1, 2, 3, 4 or 5;
[0030] p and q are independently selected from 0, 1, 2, and 3, and p and q are not 0 at the same time;
[0031] r and s are independently selected from 0, 1, 2, and 3, and r and s are not 0 at the same time.
[0032] According to some embodiments, X1 and X2 are identical or different and are independently selected from N or CRO.
[0033] According to some embodiments, X1 and X2 are identical or different and are independently selected from N or CH.
[0034] According to some embodiments, X2 and X3 are not N at the same time.
[0035] According to some embodiments, when X1 and X2 are N, X3 is CR0; when X1 is N or CR0, X2 is CR0, X3 is N or CR0; when X1 is N or CR0, X2 is N, X3 is CR0; R0 is selected from H, halogen, C 1-6 alkyl;
[0036] According to some embodiments, when X1 and X2 are N, X3 is CRO; when X1 is N or CH, X2 is CH, X3 is N or CRO; when X1 is CH, X2 is N, X3 is CRO; when X1 is N, X2 is CRO, X3 is N; R0 is selected from H, C 1-6 alkyl;
[0037] According to some embodiments, B is selected from C 1-6 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyloxy, 3-8 membered heterocyclic group, halogenated 3-8 membered heterocyclic group.
[0038] According to some embodiments, B is selected from a halogenated 6-membered N-containing heterocyclic group; for example, a halogenated piperidinyl group.
[0039] According to some embodiments, B is selected from
[0040] According to some embodiments, A is selected from unsubstituted or optionally substituted with one, two or more R a Replaced Or a fused ring group 1; the fused ring group 1 is composed of two, three, four or more rings selected from a benzene ring, a pyridine ring, an imidazole ring, a piperazine ring, a dihydropyridine ring, a tetrahydropyridine ring, a dihydropyrrole ring, a tetrahydropyrrole ring, a dihydropyran ring, a cyclobutene ring, a cyclopentene ring, a cyclohexene ring, and a cycloheptene ring.
[0041] According to some embodiments, A is selected from unsubstituted or optionally substituted with one, two or more R a Substituted with the following groups:
[0042] According to some embodiments, each R a are the same or different and are independently selected from H, OH, F, Cl, cyano, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, cyclopropyl, cyclopropylmethoxy; or, two R attached to the same ring carbon atom a Together with the carbon atoms to which they are connected, they form a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, or a cycloheptane ring.
[0043] According to some embodiments, A is selected from
[0044] According to some embodiments, ring G is selected from unsubstituted or optionally substituted with one, two or more R g The substituted fused ring group 2 is formed by condensing ring G1 and ring G2; ring G1 is selected from C 6-10 aromatic ring, 5-10 membered heteroaromatic ring, 5-10 membered heterocyclic ring; Ring G2 is selected from C 3-10 Carbon ring, C 6-10 Aromatic ring, 5-10 membered heteroaromatic ring, 3-10 membered heterocyclic ring;
[0045] According to some embodiments, ring G1 is selected from a cyclopentene ring, a cyclohexene ring, a dihydrofuran ring, a dihydropyran ring, an imidazole ring, a triazole ring, a benzene ring, a pyridine ring, a dihydropyridine ring, a pyrrole ring, a pyrazole ring, a furan ring, and a thiophene ring; preferably a benzene ring or a pyridine ring.
[0046] According to some embodiments, ring G2 is selected from a cyclopentene ring, a cyclohexene ring, a dihydrofuran ring, a dihydropyran ring, an imidazole ring, a triazole ring, a benzene ring, a pyridine ring, a pyrrole ring, a pyrazole ring, a furan ring, a thiophene ring, and a methylimidazole ring.
[0047] According to some embodiments, ring G is selected from
[0048] According to some embodiments, E is selected from unsubstituted or optionally substituted with one or two R e Substituted with the following groups: -NH-S(=O)2-R e1 、-S(=O)2-NH-R e2 、-S(=O)(=NH)-R e3 ; R e1 、R e2 、R e3 The same or different, independently selected from H, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano C 1-6 Alkyl, cyano C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 1-6 Alkoxy-C 1-6 Alkyl; each R e The same or different, independently selected from OH, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano C 1-6 Alkyl, cyano C1-6 Alkoxy.
[0049] According to some embodiments, E is selected from
[0050] According to some embodiments, M is selected from unsubstituted or optionally substituted with one, two or more R m Substituted C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl or nitrogen-containing 3-8 membered heterocyclic group; each R m the same or different, independently selected from H, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, cyano C 1- 6 alkyl, C 1-6 Alkoxy, cyano C 1-6 Alkoxy; or, two R attached to the same ring carbon atom m Together with the carbon atoms to which it is connected, it forms a saturated or partially unsaturated C 3-8 carbon ring;
[0051] According to some embodiments, M is selected from unsubstituted or optionally substituted with one, two or more R m Replaced
[0052] According to some embodiments, the compound represented by formula (I) is selected from the following structures:
[0053] wherein A, M, E, ring G, ring G1, and ring G2 are independently defined as described herein, represents a carbon-carbon single bond or a carbon-carbon double bond.
[0054] According to some embodiments, the compound represented by formula (I) has the following structure:
[0055] Among them, B, M, E, ring G, X, Z, T, X1, X2, X3, R a , n, p, q, r, s independently have the definitions described herein.
[0056] According to some embodiments, the compound represented by formula (I) has the following structure:
[0057] Among them, B, ring G, X, Z, T, X1, X2, X3, R a , n, r, s, p, q independently have the definitions described herein.
[0058] According to some embodiments, the compound represented by formula (I) has the following structure:
[0059] wherein A, ring G1, and ring G2 independently have the definitions described herein.
[0060] According to some embodiments, the compound represented by formula (I) has the following structure:
[0061] wherein A and ring G2 independently have the definitions described herein.
[0062] According to some embodiments, the compound represented by formula (I) has the following structure:
[0063] Among them, B, ring G2, X, Z, T, X1, X2, X3, R a , n, r, s, p, q independently have the definitions described herein.
[0064] According to some embodiments, the compound represented by formula (I) has the following structure:
[0065] wherein ring G2, X1, X2, and X3 independently have the definitions described herein.
[0066] According to some embodiments, the compound represented by formula (I) is selected from the following structures:
[0067] The present invention also provides a method for preparing the compound represented by formula (I), comprising the following steps:
[0068] (1) Compound a reacts with compound A-NH2 to obtain compound b;
[0069] (2) Compound b reacts with compound MH to obtain compound c;
[0070] (3) Compound C reacts with compound EH to obtain a compound represented by formula (I);
[0071] wherein A, E, M and ring G are independently defined as above; L is selected from halogen, such as Cl, Br, I; and Q is selected from halogen, such as F, Cl, Br.
[0072] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of at least one of the compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug compound thereof.
[0073] According to an embodiment of the present invention, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
[0074] According to an embodiment of the present invention, the pharmaceutical composition may further contain one or more additional therapeutic agents.
[0075] The present invention also provides a method for treating tumor diseases, comprising administering to a patient a preventive or therapeutically effective amount of at least one of the compounds represented by formula (I), its racemates, stereoisomers, tautomers, isotope-labeled substances, solvates, polymorphs, pharmaceutically acceptable salts, or prodrug compounds.
[0076] The present invention also provides a method for treating tumor diseases, comprising administering to a patient a preventive or therapeutically effective amount of the above-mentioned pharmaceutical composition.
[0077] The tumor diseases include colorectal cancer, breast cancer, lung cancer, pancreatic cancer, prostate cancer, bladder cancer, head and neck cancer, cervical cancer and ovarian cancer.
[0078] In some embodiments, the patient comprises a mammal, preferably a human.
[0079] The present invention also provides a compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or at least one of its prodrug compounds for treating tumor diseases, or a pharmaceutical composition thereof.
[0080] The present invention also provides the use of at least one of the compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug compound thereof in the preparation of a drug.
[0081] According to an embodiment of the present invention, the use may be use in preparing a medicament for treating KIF18A-mediated disorders and / or diseases, such as use in preparing a KIF18A inhibitor drug.
[0082] According to an embodiment of the present invention, the disease is, for example, cancer, including bowel cancer, breast cancer, lung cancer, pancreatic cancer, prostate cancer, bladder cancer, head and neck cancer, cervical cancer or ovarian cancer. Beneficial effects
[0083] The compound of the present invention has a good KIF18A inhibitory effect. The compound can regulate KIF18A protein alone or form a binding complex with microtubules to treat KIF18A-mediated disorders and / or diseases, such as tumor diseases, and prepare drugs for such disorders or diseases.
[0084] Through structural optimization, the present invention creatively obtains a class of structurally novel compounds, which not only have good KIF18A inhibitory effect and OVCAR-3 in vitro cell activity, but also have significantly improved physicochemical properties (solubility, permeability), and significantly improved OVCAR-3 in vivo efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0085] FIG1 is a line graph showing the effects of compound 9 of the present invention on tumor volume and body weight in OVCAR-3 mouse xenograft tumor model mice.
[0086] Definitions and Explanations of Terms
[0087] Unless otherwise indicated, the definitions of groups and terms in this specification and claims, including definitions used as examples, exemplary definitions, preferred definitions, definitions in tables, and definitions of specific compounds in the Examples, may be arbitrarily combined and coupled with one another. The group definitions and compound structures resulting from such combinations and couplings should be understood to be within the scope of this specification and / or claims.
[0088] Unless otherwise indicated, numerical ranges recited in this specification and claims are equivalent to reciting at least each specific integer value therein. For example, the numerical range "1-14" is equivalent to reciting each integer value in the numerical range "1-14", namely, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14.
[0089] The term "optional" (or "optionally", "optionally") in the general formula definitions of this application means the situation of being substituted by zero, one or more substituents, for example, "optionally substituted by one, two or more R" means that it may not be substituted by R (unsubstituted) or may be optionally substituted by one, two or more R.
[0090] "More" means three or more.
[0091] The term "C 1-12 "Alkyl" is understood to mean straight-chain and branched alkyl groups having 1 to 12 carbon atoms, "C 1-8 "Alkyl" means straight chain and branched chain alkyl groups having 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms, "C 1-6The term "alkyl" refers to straight-chain and branched alkyl groups having 1, 2, 3, 4, 5 or 6 carbon atoms. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl, or the like or isomers thereof.
[0092] The term "C 3-12 "Cycloalkyl" is understood to mean a saturated monovalent monocyclic, bicyclic (such as condensed, bridged, spiro) hydrocarbon ring or tricyclic alkane having 3 to 12 carbon atoms, preferably "C 3-10 Cycloalkyl", more preferably "C 3-8 Cycloalkyl". The term "C 3-12 "Cycloalkyl" is understood to mean a saturated monovalent monocyclic, bicyclic (eg bridged, spiro) hydrocarbon ring or tricyclic alkane having 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. 3-12 The cycloalkyl group may be a monocyclic hydrocarbon group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, or a bicyclic hydrocarbon group such as borneol, indolyl, hexahydroindolyl, tetrahydronaphthyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl, 2,7-diazaspiro[3,5]nonyl, 2,6-diazaspiro[3,4]octyl, or a tricyclic hydrocarbon group such as adamantyl.
[0093] The term "C 3-12 "Cycloalkenyl" is understood to mean a monovalent monocyclic, bicyclic (such as fused ring, bridged ring, spiro ring) or tricyclic olefin containing a carbon-carbon double bond, which has 3 to 12 carbon atoms, preferably "C 3-10 Cycloalkenyl", more preferably "C 3-8 "cycloalkenyl", which may have 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. 3-12 The cycloalkenyl group may be a monocyclic hydrocarbon group such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl or cyclodecenyl, or a bicyclic hydrocarbon group such as spiro[2.5]oct-5-enyl, spiro[3.5]non-6-enyl, spiro[4.5]dec-7-enyl.
[0094] The term "C6-14 "Aryl" is understood to mean preferably a monovalent aromatic or partially aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring having 6 to 14 carbon atoms, which may be a single aromatic ring or polyaromatic rings fused together, preferably "C 6-10 Aryl". The term "C 6-14 "Aryl" is understood to mean preferably a monovalent aromatic or partially aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring ("C 6-14 or a ring having 9 carbon atoms ("C9 aryl"), for example indanyl or indenyl, or a ring having 10 carbon atoms ("C 10 aryl) such as tetrahydronaphthyl, dihydronaphthyl or naphthyl, or a ring having 13 carbon atoms ("C 13 aryl), such as fluorenyl, or a ring having 14 carbon atoms ("C 14 aryl”), such as anthracenyl. When the C 6-20 When the aryl group is substituted, it may be monosubstituted or polysubstituted. Furthermore, there is no limitation on the position of substitution, and for example, substitution may be at the ortho, para or meta position.
[0095] The term "5-14 membered heteroaryl" is understood to include monovalent monocyclic, bicyclic (e.g. fused, bridged, spiro) or tricyclic aromatic ring systems having 5 to 14 ring atoms and containing 1 to 5 heteroatoms independently selected from N, O and S, for example "5-10 membered heteroaryl". The term "5-14 membered heteroaryl" is understood to include monovalent monocyclic, bicyclic or tricyclic aromatic ring systems having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, in particular 5 or 6 or 9 or 10 carbon atoms, and containing 1 to 5, preferably 1 to 3, heteroatoms each independently selected from N, O and S and, in each case, may additionally be benzofused. "Heteroaryl" also refers to a radical in which a heteroaromatic ring is fused to one or more aryl, alicyclic or heterocyclyl rings, wherein the radical or point of attachment is on the heteroaromatic ring. Non-limiting examples include 1-, 2-, 3-, 5-, 6-, 7-, or 8-indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-indazolyl, 2-, 4-, 5-, 6-, 7-, or 8-purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-quinolizinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4- , 5-, 6-, 7- or 8-isoquinolyl, 1-, 4-, 5-, 6-, 7- or 8-phthalazinyl, 2-, 3-, 4-, 5- or 6-naphthyridinyl, 2-, 3-, 5-, 6-, 7- or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 6- or 7-pteridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-4aHcarbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-4aHcarbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-oxo-1-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-oxo-1-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-oxo-1-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-oxo-1-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-oxo-1-carbazolyl, -phenazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenothiazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenazinyl, 2-, 3-, 4-, 5-, 6-, or 1-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-benzoisoquinolinyl, 2-, 3-, 4-, or thieno[2,3-b]furanyl, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-, or 11-7H-pyrazino[2,3-c]carbazolyl, 2-, 3-, 5-, 6- or 7-2H-furo[3,2-b]-pyranyl, 2-, 3-, 4-, 5-, 7- or 8-5H-pyrido[2,3-d]-o-oxazinyl, 1-, 3- or 5-1H-pyrazolo[4,3-d]oxazolyl, 2-, 4- or 54H-imidazo[4,5-d]thiazolyl, 3-, 5- or 8-pyrazino[2,3-d]pyridazinyl, 2-, 3-, 5- or 6-imidazo[2,1-b]thiazolyl, 1-, 3-, 6-, 7-, 8- or 9-furo[3,4-c]cinnolinyl, 1-, 2-, 3-, 4-, 5-, 6-, 8-, 9-, 10 or 11-4H-pyrido[2,3
[0015] In some embodiments, the present invention further comprises carbazolyl, 2-, 3-, 6-, or 7-imidazo[1,2-b][1,2,4]triazinyl, 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 4-, 5-, 6-, or 7-benzothiazolyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-benzoxapinyl, 2-, 4-, 5-, 6-, 7-, or 8-benzoxazinyl, 1-, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-, or 11-4H-pyrrolo[1,2-b][2]benzazepinyl. Typical fused heteroaryl groups include, but are not limited to, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, and 2-, 4-, 5-, 6-, or 7-benzothiazolyl. When the 5- to 14-membered heteroaryl group is linked to other groups to form a compound of the present invention, the carbon atoms on the 5- to 14-membered heteroaryl ring may be linked to the other groups, or heteroatoms on the 5- to 14-membered heteroaryl ring may be linked to the other groups. When the 5- to 14-membered heteroaryl group is substituted, it may be monosubstituted or polysubstituted. Furthermore, there is no limitation on the substitution site, for example, a hydrogen atom connected to a carbon atom on a heteroaryl ring may be substituted, or a hydrogen atom connected to a heteroatom on a heteroaryl ring may be substituted.
[0096] Unless otherwise defined, the term "3-14 membered heterocyclyl" refers to a saturated or unsaturated non-aromatic ring or ring system, for example, a 4-, 5-, 6- or 7-membered monocyclic ring, a 7-, 8-, 9-, 10-, 11- or 12-membered bicyclic ring (such as a fused ring, a bridged ring, a spirocyclic ring) or a 10-, 11-, 12-, 13- or 14-membered tricyclic ring system, and contains at least one, for example 1, 2, 3, 4, 5 or more heteroatoms selected from O, S and N, wherein N and S may also be optionally oxidized to various oxidation states to form nitrogen oxides, -S(O)- or -S(O)2- states. Preferably, the heterocyclyl may be selected from "3-10 membered heterocyclyl". The term "3-10 membered heterocyclyl" means a saturated or unsaturated non-aromatic ring or ring system, and contains at least one heteroatom selected from O, S and N. The heterocyclic group can be connected to the rest of the molecule by any one of the carbon atoms or nitrogen atom (if present). The heterocyclic group can include fused or bridged rings and spirocyclic rings. In particular, the heterocyclic group can include but is not limited to: 4-membered rings, such as azetidinyl, oxetane; 5-membered rings, such as tetrahydrofuranyl, dioxolyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl; or 6-membered rings, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl or trithianyl; or 7-membered rings, such as diazepanyl. Optionally, the heterocyclic group can be benzo-fused. The heterocyclic group may be bicyclic, such as, but not limited to, a 5,5-membered ring, such as a hexahydrocyclopenta[c]pyrrol-2(1H)-yl ring, or a 5,6-membered bicyclic ring, such as a hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl ring. The heterocyclic group may be partially unsaturated, i.e., it may contain one or more double bonds, such as, but not limited to, dihydrofuranyl, dihydropyranyl, 2,5-dihydro-1H-pyrrolyl, 4H-[1,3,4]thiadiazinyl, 1,2,3,5-tetrahydrooxazolyl, or 4H-[1,4]thiazinyl, or it may be benzo-fused, such as, but not limited to, dihydroisoquinolinyl. When the 3-14-membered heterocyclic group is linked to other groups to form the compounds of the present invention, the linking may be to a carbon atom of the 3-14-membered heterocyclic group or to a heterocyclic atom on the 3-14-membered heterocyclic group ring. For example, when the 3-14 membered heterocyclic group is selected from piperazinyl, the nitrogen atom on the piperazinyl group may be connected to the other group. Or when the 3-14 membered heterocyclic group is selected from piperidinyl, the nitrogen atom on the piperidinyl ring and the carbon atom at the para position thereof may be connected to the other group.
[0097] The term "spirocyclic" refers to a ring system in which two rings share one ring atom.
[0098] The term "fused ring" refers to a ring system in which two rings share two ring atoms.
[0099] The term "bridged ring" refers to a ring system in which two rings share three or more ring atoms.
[0100] The term "halogen" refers to fluorine, chlorine, bromine and iodine.
[0101] "Halo" means substituted with one or more halogens.
[0102] When ring G is selected from When the substituents are substituted, it has three connection sites. Generally speaking, the three connection sites can be connected to A, M, and E in the general structure respectively. For example, the connection position 1 is connected to A, the connection position 2 is connected to M, and the connection position 3 is connected to E. When other substituents are selected for ring G and ring G1, the same explanation as above shall apply.
[0103] Those skilled in the art will appreciate that when A is selected from the group consisting of unsubstituted or optionally substituted with one, two or more R a Replaced When R a It can be located at any position on the ring where X1 is located. For example, when X1 is CH, R a Can replace H on X1 to form CR a .
[0104] It will be appreciated by those skilled in the art that the compounds of formula (I) may exist in the form of various pharmaceutically acceptable salts. If these compounds have a basic center, they may form acid addition salts; if these compounds have an acidic center, they may form base addition salts; if these compounds contain both an acidic center (e.g., a carboxyl group) and a basic center (e.g., an amino group), they may also form internal salts.
[0105] The compounds of the present invention may exist in the form of solvates (e.g., hydrates), wherein the compounds of the present invention contain a polar solvent as a structural element of the crystal lattice of the compound, in particular water, methanol or ethanol. The amount of polar solvent, in particular water, may be present in a stoichiometric or non-stoichiometric ratio.
[0106] Depending on their molecular structure, the compounds of the present invention may be chiral and therefore may exist in various enantiomeric forms. Thus, these compounds may exist in racemic or optically active forms. The compounds of the present invention encompass isomers or mixtures thereof, racemates, in which each chiral carbon is in the R or S configuration. The compounds of the present invention or their intermediates can be separated into enantiomeric compounds by chemical or physical methods well known to those skilled in the art, or used in this form for synthesis. In the case of racemic amines, diastereomers are prepared from the mixture by reaction with an optically active resolving agent. Examples of suitable resolving agents are optically active acids, such as R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, appropriate N-protected amino acids (e.g., N-benzoylproline or N-phenylsulfonylproline) or various optically active camphorsulfonic acids. Chromatographic enantiomer resolution can also be advantageously performed with the aid of optically active resolving agents (e.g., dinitrobenzoylphenylglycine, cellulose triacetate or other carbohydrate derivatives or chirally derivatized methacrylate polymers immobilized on silica gel). Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, e.g., hexane / isopropanol / acetonitrile.
[0107] The corresponding stable isomers can be separated according to known methods, for example by extraction, filtration or column chromatography.
[0108] The term "patient" refers to any animal including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses or primates, and most preferably humans.
[0109] The term "therapeutically effective amount" refers to that amount of an active compound or drug that will elicit the biological or medical response that a researcher, veterinarian, physician, or other clinician is seeking in a tissue, system, animal, individual, or human, and includes one or more of the following: (1) prevents disease, e.g., prevents a disease, disorder, or condition in an individual who is susceptible to the disease, disorder, or condition but who is not yet experiencing or developing the pathology or symptoms of the disease. (2) inhibits disease, e.g., inhibits the disease, disorder, or condition (i.e., prevents further development of the pathology and / or symptoms) in an individual who is experiencing or developing the pathology or symptoms of the disease, disorder, or condition. (3) alleviates disease, e.g., alleviates the disease, disorder, or condition (i.e., reverses the pathology and / or symptoms) in an individual who is experiencing or developing the pathology or symptoms of the disease, disorder, or condition. DETAILED DESCRIPTION
[0110] The technical solutions of the present invention will be described in further detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are encompassed within the scope of protection that the present invention is intended to protect.
[0111] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0112] Example 1
[0113] 5-{6-azaspiro[2.5]octan-6-yl}-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-7-(2-hydroxyethanesulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (Compound 1)
[0114] The first step is the synthesis of 2-bromo-4-fluoro-5-methoxybenzaldehyde (compound 1-2):
[0115] To a solution of 4-fluoro-3-methoxybenzaldehyde (10 g, 64.876 mmol, 1 eq) in water (20 mL) was added potassium bromide (38.60 g, 324.380 mmol, 5 eq) at room temperature, followed by elemental bromine (9.98 mL, 194.628 mmol, 3 eq). Stirring was continued at room temperature for 15 hours. The precipitated solid was collected by filtration and washed with water (3 × 5 mL). Drying under vacuum gave 2-bromo-4-fluoro-5-methoxybenzaldehyde (15 g, 99.22%) as a solid.
[0116] 1 H NMR (400MHz, DMSO-d6) δ10.13(d,J=0.8Hz,1H),7.83(dd,J=10.4,1.6Hz,1H),7.57-7.54(dd,J=10.4,1.6Hz,1H),3.92(s,3H).
[0117] Step 2: Synthesis of 3-(2-bromo-4-fluoro-5-methoxyphenyl)propionic acid (Compound 1-4):
[0118] Under nitrogen, to a solution of 2-bromo-4-fluoro-5-methoxybenzaldehyde (8 g, 34.329 mmol, 1 eq) in formic acid (10 mL) was added Melchine's acid (compound 1-3) (4947.77 mg, 34.329 mmol, 1 eq) at room temperature, followed by the dropwise addition of triethylamine (14.32 mL, 102.987 mmol, 3 eq). The reaction mixture was heated to 100°C and stirred for 10 hours. After completion of the reaction, the mixture was quenched with water at room temperature and extracted with ethyl acetate (3 × 200 mL). The combined organic phases were washed with saturated sodium chloride solution (1 × 300 mL) and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with petroleum ether:ethyl acetate (1:1) to afford 3-(2-bromo-4-fluoro-5-methoxyphenyl)propanoic acid (2.8 g, 29.44%).
[0119] MS (ESI, m / z): 275.05 [MH] - ,RT(min):0.886.
[0120] Step 3: Synthesis of 4-bromo-6-fluoro-7-methoxy-2,3-dihydroindan-1-one (Compound 1-5):
[0121] Under nitrogen, trifluoromethanesulfonic acid (3.19 mL, 36.090 mmol, 5 eq) was added dropwise to a solution of 3-(2-bromo-4-fluoro-5-methoxyphenyl)propanoic acid (2.0 g, 7.218 mmol, 1 eq) in 1,2-dichloroethane (12 mL) at room temperature. The reaction mixture was heated to 80°C and microwaved for 1 hour. The reaction mixture was quenched with water at room temperature and extracted with dichloromethane (3 × 60 mL). The combined organic phases were backwashed with saturated brine (1 × 60 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (10:1) to afford 4-bromo-6-fluoro-7-methoxy-2,3-dihydroindan-1-one (1.5 g, 80.22%).
[0122] MS (ESI, m / z): 259.15 [M+H] + ,RT(min):1.030.
[0123] 1 H NMR (400MHz, CDCl3-d) δ7.51 (d, J = 11.2Hz, 1H), 4.09 (s, 3H), 2.99-2.96 (m, 2H), 2.77-2.74 (m, 2H).
[0124] Step 4: Synthesis of 7-bromo-5-fluoro-4-methoxy-2,3-dihydro-1H-indene (Compound 1-6):
[0125] Under nitrogen, triethylsilane (3.74 mL, 23.160 mmol, 3 eq) was added to a solution of 4-bromo-6-fluoro-7-methoxy-2,3-dihydroindan-1-one (2 g, 7.720 mmol, 1 eq) in trifluoroacetic acid (8.80 mL) at 0°C. The reaction mixture was then heated and stirred at 50°C for 16 hours, monitored by thin-layer chromatography. The reaction mixture was quenched with water at room temperature. The reaction mixture was extracted with ethyl acetate (3 × 60 mL). The combined organic phases were backwashed with saturated brine (1 × 60 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (10:1) to yield 7-bromo-5-fluoro-4-methoxy-2,3-dihydro-1H-indene (1.5 g, 79.28%).
[0126] 1 H NMR (400 MHz, deuterated chloroform) δ 7.06 (d, J = 10.8 Hz, 1H), 3.91 (s, 3H), 3.03-2.99 (m, 2H), 2.90-2.83 (m, 2H), 2.14-2.07 (m, 2H).
[0127] Step 5: Synthesis of 7-bromo-5-fluoro-2,3-dihydro-1H-indene-4-ol (Compound 1-7):
[0128] 7-Bromo-5-fluoro-4-methoxy-2,3-dihydro-1H-indene (800 mg, 3.264 mmol, 1 eq) and a solution of hydrogen bromide in acetic acid (8.00 mL) were heated and stirred at 100°C for 2 hours. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (50 mL). The reaction mixture was washed sequentially with distilled water (1 × 30 mL), saturated sodium bicarbonate (1 × 30 mL), and saturated brine (1 × 30 mL). The organic phase was dried over anhydrous sodium sulfate, the resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was used in the next step without further purification.
[0129] MS (ESI, m / z): 231.05 [MH] - ,RT(min):1.041
[0130] Step 6: Synthesis of 7-bromo-5-fluoro-2,3-dihydro-1H-inden-4-yl trifluoromethanesulfonate (Compound 1-9):
[0131] Under nitrogen, pyridine (1.54 g, 19.474 mmol, 1.50 eq) was added to a solution of 7-bromo-5-fluoro-2,3-dihydro-1H-inden-4-ol (3 g, 12.983 mmol, 1 eq) in dichloromethane (30.00 mL) at 0°C and stirred for 10 minutes. Trifluoromethanesulfonic anhydride (Compound 1-8) (3.29 mL, 19.474 mmol, 1.50 eq) was then added and stirred at room temperature overnight. The reaction mixture was quenched with water at room temperature. The reaction mixture was extracted with ethyl acetate (3 × 80 mL). The combined organic phases were backwashed with saturated brine (1 × 100 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (10:1) to give 7-bromo-5-fluoro-2,3-dihydro-1H-inden-4-yl trifluoromethanesulfonate (2 g, 42.42%).
[0132] 1 H NMR (400 MHz, deuterated chloroform) δ 7.23 (d, J = 9.2 Hz, 1H), 3.18-3.14 (m, 2H), 2.99-2.95 (m, 2H), 2.23-2.16 (m, 2H).
[0133] Step 7: Synthesis of methyl 7-bromo-5-fluoro-2,3-dihydro-1H-indene-4-carboxylate (Compound 1-10):
[0134] To a solution of 7-bromo-5-fluoro-2,3-dihydro-1H-inden-4-yl trifluoromethanesulfonate (1.2 g, 3.305 mmol, 1 eq) in dimethyl sulfoxide / methanol (7.5 mL, 3 / 2, v / v) was added palladium acetate (74.19 mg, 0.331 mmol, 0.1 eq), bis(diphenylphosphinobutane) (140.94 mg, 0.331 mmol, 0.1 eq), and triethylamine (1148.39 uL, 8.263 mmol, 2.5 eq) in sequence at room temperature under nitrogen. The reaction mixture was heated to 80°C while carbon monoxide was introduced for 1 hour. The reaction mixture was quenched with water at room temperature and extracted with ethyl acetate (3 × 10 mL). The organic phases were combined, backwashed with saturated brine (1 × 10 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (10:1) to give methyl 7-bromo-5-fluoro-2,3-dihydro-1H-indene-4-carboxylate (400 mg, 44.32%).
[0135] 1H NMR (400 MHz, deuterated chloroform) δ 7.14 (d, J = 10.0 Hz, 1H), 3.91 (s, 3H), 3.25 (t, J = 7.6 Hz, 2H), 2.90 (t, J = 7.6 Hz, 2H), 2.16-2.08 (m, 2H).
[0136] Step 8 Synthesis of 7-bromo-5-fluoro-2,3-dihydro-1H-indene-4-carboxylic acid (Compound 1-11):
[0137] To a solution of methyl 7-bromo-5-fluoro-2,3-dihydro-1H-indene-4-carboxylate (500 mg, 1.831 mmol, 1 eq) in tetrahydrofuran / water (4 mL, 3 / 1, v / v) was added lithium hydroxide (131.54 mg, 5.493 mmol, 3 eq) at room temperature. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water at room temperature and acidified to pH 5-6 with 1 M hydrochloric acid. The reaction mixture was extracted with ethyl acetate (3 x 30 mL). The combined organic phases were backwashed with saturated brine (1 x 40 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product / resulting mixture was used in the next step without further purification.
[0138] MS (ESI, m / z): 257.10 [MH] - ,RT(min):1.053
[0139] Step 9 Synthesis of 7-bromo-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-5-fluoro-2,3-dihydro-1H-indene-4-carboxamide (Compound 1-13):
[0140] Under nitrogen, tetramethylchloroformamidine hexafluorophosphate (2166.02 mg, 7.720 mmol, 4 eq) and N-methylimidazole (1584.61 mg, 19.300 mmol, 10 eq) were added to a dichloromethane solution (5 mL) of 7-bromo-5-fluoro-2,3-dihydro-1H-indene-4-carboxylic acid (500 mg, 1.930 mmol, 1 eq) and 2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-amine (Compound 1-12) (660.76 mg, 2.895 mmol, 1.5 eq) at room temperature. The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water at room temperature and extracted with dichloromethane (3 × 30 mL). The organic phases were combined, backwashed with saturated brine (1 × 10 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (10:1) to give 7-bromo-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-5-fluoro-2,3-dihydro-1H-indene-4-carboxamide (160 mg, 17.67%).
[0141] MS (ESI, m / z): 469.25 [M+H] + ,RT(min):1.455.
[0142] Step 10 Synthesis of 5-{6-azaspiro[2.5]octane-6-yl}-7-bromo-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-2,3-dihydro-1H-indene-4-carboxamide (Compound 1-15):
[0143] Under nitrogen, sodium tert-butoxide (196.59 mg, 2.046 mmol, 6 eq) was added to a solution of 7-bromo-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-5-fluoro-2,3-dihydro-1H-indene-4-carboxamide (160 mg, 0.341 mmol, 1 eq) and 6-azaspiro[2.5]octane hydrochloride (Compound 1-14) (251.69 mg, 1.705 mmol, 5 eq) in N,N-dimethylacetamide (10 mL) at room temperature. The reaction mixture was heated to 140°C and allowed to react for 3 days. The reaction mixture was cooled to room temperature and quenched with water. The reaction mixture was extracted with ethyl acetate (3 × 30 mL). The combined organic phases were backwashed with saturated brine (1 × 30 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (10:1) to give 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-2,3-dihydro-1H-indene-4-carboxamide (48 mg, 25.12%).
[0144] MS(ESI,m / z):560.60[M+H]+,RT(min):1.494.
[0145] 1 H NMR (400 MHz, deuterated chloroform) δ 12.69 (s, 1H), 7.46 (s, 1H), 7.27 (s, 1H), 3.99 (d, J = 7.2 Hz, 4H), 3.47 (t, J = 7.6 Hz, 2H), 3.03 (t, J = 5.4 Hz, 4H), 2.93 (t, J = 7.6 Hz, 2H), 2.37 (s, 3H), 2.10 (q, J = 7.6 Hz, 2H), 1.99 (s, 4H), 1.55 (s, 4H), 0.38 (s, 4H).
[0146] Step 11: Synthesis of 5-{6-azaspiro[2.5]octan-6-yl}-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-7-(2-hydroxyethanesulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (Compound 1):
[0147] To a solution of 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-2,3-dihydro-1H-indene-4-carboxamide (45 mg, 0.080 mmol, 1 eq) in 1,4-dioxane (2 mL) were added dicyclohexyl(3-isopropoxy-2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphane (Ephos, 8.59 mg, 0.016 mmol, 0.2 eq), (methanesulfonic acid {dicyclohexyl(3-isopropoxy-2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphane}(2'-methylamino-1,1'- Biphenyl-2-yl) palladium (II) (Ephos-Pd-G4, 7.37 mg, 0.008 mmol, 0.1 eq), cesium carbonate (78.48 mg, 0.240 mmol, 3 eq) and 2-hydroxyethanesulfonamide (Compound 1-16) (12.06 mg, 0.096 mmol, 1.2 eq). The reaction solution was heated to 100 ° C and heated for 1 hour. The reaction solution was cooled to room temperature and the reaction mixture was quenched with water at room temperature. The reaction mixture was extracted with ethyl acetate (3×10 mL). The organic phases were combined, backwashed with saturated brine (1×10 mL), and dried over anhydrous sodium sulfate. After the obtained mixture was filtered, the filtrate was concentrated under reduced pressure. The crude product was purified by high performance liquid chromatography under the following conditions (chromatographic column specifications: XBridge Prep OBD C18 Column, 30*150 mm, 5 μm; Mobile phase A: water (10 mmol / L ammonium bicarbonate), Mobile phase B: acetonitrile; Flow rate: 60 mL / min; Elution gradient: 48% B to 80% B, 80% B over 8 min; Detection wavelength: UV 220 nm; Retention time (min): 7.88). Compound 1 (21.93 mg, 44.81%) was obtained.
[0148] MS (ES, m / z): 605.45 [M+H] + ,RT(min):1.894.
[0149] 1 H NMR: (400MHz, DMSO-d6) δ12.92(s,1H),9.39(s,1H),7.38(s,1H),7.27(s,1H),4.99(s,1H),3.90(s,4H),3.77(t,J=6.5Hz,2H),3 .31(s,2H),3.22(t,J=7.5Hz,2H),2.94(s,4H),2.85(t,J=7.5Hz,2H),2.31(s,3H),2.05-1.86(m,6H),1.65(s,4H),0.36(s,4H).
[0150] Example 2
[0151] 5-{6-azaspiro[2.5]octan-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-7-(2-hydroxyethanesulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (Compound 9)
[0152] The first step is the synthesis of 7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-5-fluoro-2,3-dihydro-1H-indene-4-carboxamide (compound 9-2):
[0153] Under nitrogen, N-methylimidazole (475.38 mg, 5.790 mmol, 10 eq) was added to a solution of 6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-amine (197.37 mg, 0.868 mmol, 1.5 eq), N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (649.81 mg, 2.316 mmol, 4 eq), and 7-bromo-5-fluoro-2,3-dihydro-1H-indene-4-carboxylic acid (150 mg, 0.579 mmol, 1.00 eq) in dichloromethane (7.5 mL) at room temperature. The reaction mixture was heated to 60°C and stirred for 1 hour. The reaction mixture was cooled to room temperature and extracted with dichloromethane (3 × 50 mL). The organic phases were combined, backwashed with saturated brine (1 × 50 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (5:1) to give 7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-5-fluoro-2,3-dihydro-1H-indene-4-carboxamide (180 mg, 66.38%).
[0154] MS:(ESI,m / z):468.30[M+H] + ,RT(min):1.397.
[0155] Step 2 Synthesis of 5-{6-azaspiro[2.5]octane-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (Compound 9-3):
[0156] Under nitrogen, sodium tert-butoxide (82.08 mg, 0.855 mmol, 5 eq) was added to a solution of 7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-5-fluoro-2,3-dihydro-1H-indene-4-carboxamide (80 mg, 0.171 mmol, 1 eq) and 6-azaspiro[2.5]octane hydrochloride (126.11 mg, 0.855 mmol, 5 eq) in N,N-dimethylacetamide (4 mL) at room temperature. The reaction mixture was heated to 140°C and stirred for 48 hours. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (3 × 50 mL). The organic phases were combined, backwashed with saturated brine (3 × 50 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative chromatography using petroleum ether / ethyl acetate (1:1) to afford 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (50 mg, 52.31%).
[0157] MS:(ESI,m / z):559.45[M+H] + ,RT(min):1.590.
[0158] Step 3: Synthesis of 5-{6-azaspiro[2.5]octane-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-7-(2-hydroxyethanesulfonyl)-2,3-dihydro-1H-indene-4-carboxamide (Compound 9):
[0159] Under nitrogen protection, 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (45 mg, 0.080 mmol, 1 eq) and 2-hydroxyethanesulfonamide (20.13 mg, 0.160 mmol, 2 eq) were added to a mixture of 1H-indene-4-carboxamide (45 mg, 0.080 mmol, 1 eq) and 2-hydroxyethanesulfonamide (20.13 mg, 0.160 mmol, 2 eq) at room temperature. , 4-dioxane (4.5 mL) solution, added dicyclohexyl (3-isopropoxy-2', 4', 6'-triisopropyl-[1,1'-biphenyl]-2-yl) phosphane (8.6 mg, 0.016 mmol, 0.2 eq), (methanesulfonic acid {dicyclohexyl (3-isopropoxy-2', 4', 6'-triisopropyl-[1,1'-biphenyl]-2-yl) phosphane} (2' 1,1'-biphenyl-2-yl)palladium(II) (7.39 mg, 0.008 mmol, 0.1 eq) and cesium carbonate (78.62 mg, 0.240 mmol, 3 eq). The reaction mixture was heated to 100°C and stirred for 1 hour. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (3 × 10 mL). The organic phases were combined, backwashed with saturated brine (1 × 10 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC to yield 5-{6-azaspiro[2.5]octan-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-7-(2-hydroxyethanesulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (8.8 mg, 17.98%).
[0160] MS:(ESI,m / z):604.40[M+H] + ,RT(min):1.861.
[0161] 1 H NMR: (400MHz, DMSO-d6) δ12.16(s,1H),9.31(s,1H),7.46(s,1H),7.22(s,1 H),6.53(s,1H),4.96(s,1H),3.77(t,J=6.5Hz,2H),3.71(t,J=5.8Hz,4H),3 .33(s,1H),3.29(s,1H),3.21(t,J=7.5Hz,2H),2.94(t,J=5.3Hz,4H),2.85 (t,J=7.5Hz,2H),2.26(s,3H),2.05-1.88(m,6H),1.63(s,4H),0.34(s,4H).
[0162] Example 3
[0163] 5-(6-Azaspiro[2.5]octan-6-yl)-N-[6-(4,4-difluoropiperidin-1-yl)pyridin-2-yl]-7-(2-hydroxyethanesulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (Compound 8)
[0164] The first step is the synthesis of 5-(6-azaspiro[2.5]octane-6-yl)-7-bromo-2,3-dihydro-1H-indene-4-carboxylic acid (Compound 8-1):
[0165] Under nitrogen, sodium tert-butoxide (77.50 mg, 0.805 mmol, 5 eq) was added to a solution of 7-bromo-5-fluoro-2,3-dihydro-1H-indene-4-carboxylic acid (50 mg, 0.161 mmol, 1 eq) in N-methylpyrrolidone (1 mL) at room temperature. After stirring for 2 minutes, 6-azaspiro[2.5]octane hydrochloride (89.66 mg, 0.805 mmol, 5 eq) was added at room temperature. The reaction system was heated to 160°C and allowed to react for 4 hours. The reaction solution was cooled to room temperature and extracted with ethyl acetate (3 × 10 mL). The organic phases were combined, backwashed with saturated brine (1 × 10 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (3:1) to give 5-(6-azaspiro[2.5]octan-6-yl)-7-bromo-2,3-dihydro-1H-indene-4-carboxylic acid (30 mg, 53.11%).
[0166] MS:(ESI,m / z):377.00[M+H] + ,RT(min):0.827
[0167] Step 2 Synthesis of 5-(6-azaspiro[2.5]octane-6-yl)-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)pyridin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (Compound 8-3):
[0168] Under nitrogen, to a solution of 5-(6-azaspiro[2.5]octan-6-yl)-7-bromo-2,3-dihydro-1H-indene-4-carboxylic acid (20 mg, 0.057 mmol, 1 eq) in dichloromethane (1 mL) was added 6-(4,4-difluoropiperidin-1-yl)pyridin-2-amine (9.13 mg, 0.044 mmol, 1.5 eq), tetramethylchlorouronium hexafluorophosphate (64.09 mg, 0.228 mmol, 4 eq), and N-methylimidazole (46.88 mg, 0.570 mmol, 10 eq) at room temperature. The reaction mixture was heated to 80°C for 1 hour. The reaction mixture was cooled to room temperature and extracted with dichloromethane (3 × 10 mL). The organic phases were combined, backwashed with saturated brine (1 × 10 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (3:1) to give 5-(6-azaspiro[2.5]octan-6-yl)-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)pyridin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (30 mg, 96.32%).
[0169] MS:(ESI,m / z):365.90[M+H] + ,RT(min):1.140
[0170] Step 3: Synthesis of 5-(6-azaspiro[2.5]octane-6-yl)-N-[6-(4,4-difluoropiperidin-1-yl)pyridin-2-yl]-7-(2-hydroxyethanesulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (Compound 8):
[0171] To a solution of 5-(6-azaspiro[2.5]octan-6-yl)-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)pyridin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (25 mg, 0.046 mmol, 1 eq) in 1,4-dioxane (1 mL, 11.804 mmol, 257.55 eq) was added bicyclohexyl(3-isopropoxy-2′,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphane (4.90 mg, 0.009 mmol, 0.2 eq), (methanesulfonic acid {bicyclohexyl(3-isopropoxy-2′,4′,6′-triisopropyl-[1,1 '-biphenyl]-2-yl)phosphine}(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (4.21 mg, 0.005 mmol, 0.1 eq), cesium carbonate (44.80 mg, 0.138 mmol, 3 eq) and 2-hydroxyethanesulfonamide (8.60 mg, 0.069 mmol, 1.5 eq). The reaction solution was heated to 100 ° C and stirred for 1 hour. The reaction solution was cooled to room temperature and extracted with ethyl acetate (3×10 mL). The organic phases were combined, backwashed with saturated brine (1×10 mL), and dried over anhydrous sodium sulfate. After the obtained mixture was filtered, the filtrate was concentrated under reduced pressure. The crude product was purified by high performance liquid chromatography under the following conditions (chromatographic column kinete 5μm EVO C18, 30mm*150mm, mobile phase A: water (10mmol / L ammonium bicarbonate), mobile phase B: acetonitrile, flow rate: 60mL / min, elution gradient: 40%B to 75%B in 8min; 254nm; Rt: 6.9min) to obtain 5-(6-azaspiro[2.5]octan-6-yl)-N-[6-(4,4-difluoropiperidin-1-yl)pyridin-2-yl]-7-(2-hydroxyethanesulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (2.79mg, 10.29%).
[0172] MS:(ESI,m / z):590.05[M+H] + ,RT(min):1.874
[0173] 1H-NMR: (400MHz, DMSO-d6) δ12.30(s,1H),9.34(s,1H),7.61–7.54(m,2H),7.22(s,1H),6.70–6.63(m,1H),4.99(s,1H),3.77(t,J=6.5Hz,2H),3 .72(t,J=5.7Hz,4H),3.30(s,2H),3.22(t,J=7.5Hz,2H),3.03–2.89(m, 4H), 2.83 (t, J = 7.5Hz, 2H), 2.09–1.90 (m, 6H), 1.64 (s, 4H), 0.35 (s, 4H).
[0174] Example 4
[0175] 5-{6-Azaspiro[2.5]octan-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)pyrazin-2-yl]-7-(2-hydroxyethanesulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (Compound 13)
[0176] The first step is the synthesis of 5-{6-azaspiro[2.5]octane-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)pyrazin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (Compound 13-2):
[0177] Under nitrogen, to a solution of 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-2,3-dihydro-1H-indene-4-carboxylic acid (25 mg, 0.071 mmol, 1 eq) and 6-(4,4-difluoropiperidin-1-yl)pyrazin-2-amine (18.35 mg, 0.085 mmol, 1.2 eq) in dichloromethane (5 mL) was added N,N,N,N-tetramethylchloroformamidine hexafluorophosphate (80.11 mg, 0.284 mmol, 4 eq) and N-methylimidazole (58.60 mg, 0.710 mmol, 10 eq) at room temperature. The reaction mixture was heated to 80°C and stirred for 1 hour. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (3 × 5 mL). The organic phases were combined, backwashed with saturated brine (1 × 10 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (3:1) to give 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)pyrazin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (25 mg, 39.19%).
[0178] MS:(ESI,m / z):548.05[M+H]+ ,RT(min):1.255
[0179] Step 2 Synthesis of 5-{6-azaspiro[2.5]octan-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)pyrazin-2-yl]-7-(2-hydroxyethanesulfonyl)-2,3-dihydro-1H-indene-4-carboxamide (Compound 13):
[0180] To a solution of 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)pyrazin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (25 mg, 0.046 mmol, 1 eq) and 2-hydroxyethanesulfonamide (11.6 mg, 0.092 mmol, 2 eq) in 1,4-dioxane (5 mL) was added bicyclohexyl (3-isopropoxy-2′,4′,6′-triisopropyl-[1,1′ The reaction mixture was heated to 100°C and stirred for 1 hour. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (3 × 5 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (2 × 5 mL), and dried over anhydrous sodium sulfate. The filtrate was filtered and concentrated under reduced pressure. The resulting residue was purified by preparative HPLC under the following conditions: column specifications: Ultimate 5 μM XB-C18; mobile phase A: water (10 mmol / L sodium bicarbonate), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 35% B to 60% B in 22 min; detection wavelength: 254 nm / 220 nm; retention time (min): 7.55 to obtain 5-{6-azaspiro[2.5]octan-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)pyrazin-2-yl]-7-(2-hydroxyethanesulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (2.23 mg, 8.17%).
[0181] MS:(ESI,m / z):591.20[M+H] + ,RT(min):1.754
[0182] 1H NMR (400MHz, DMSO-d6) δ12.99(s,1H),8.76(s,1H),8.16(s,1H),7.24(s,1H),5.00(s,1H),3.77(d,J=6.5Hz,6H) ,3.24(m,4H),2.95(d,J=5.3Hz,4H),2.80(t,J=7.6Hz,2H),2.05(m,4H),1.95(m,2H),1.64(s,4H),0.36(s,4H).
[0183] Example 5
[0184] 5-(6-Azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-3-fluoropyridin-4-yl]-7-(2-hydroxyethylsulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (Compound 27)
[0185] The first step is the synthesis of 5-(6-azaspiro[2.5]octane-6-yl)-7-bromo-N-[2-(4,4-difluoropiperidin-1-yl)-3-fluoropyridin-4-yl]-2,3-dihydro-1H-indene-4-carboxamide (compound 27-2):
[0186] Under nitrogen, to a solution of 5-(6-azaspiro[2.5]octan-6-yl)-7-bromo-2,3-dihydro-1H-indene-4-carboxylic acid (25 mg, 0.071 mmol, 1 eq) and 2-(4,4-difluoropiperidin-1-yl)-3-fluoropyridin-4-amine (18.15 mg, 0.078 mmol, 1.1 eq) in dichloromethane (2 mL) was added N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (80.11 mg, 0.284 mmol, 4 eq) and 1-methylimidazole (58.60 mg, 0.710 mmol, 10 eq) at room temperature. The mixture was heated to 60°C and stirred for 1 hour. The reaction mixture was diluted with water (10 mL) and extracted with dichloromethane (3 × 10 mL). The organic phases were combined, backwashed with saturated brine (1 × 10 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (10:1) to obtain 5-(6-azaspiro[2.5]octan-6-yl)-7-bromo-N-[2-(4,4-difluoropiperidin-1-yl)-3-fluoropyridin-4-yl]-2,3-dihydro-1H-indene-4-carboxamide (35 mg, 85.25%).
[0187] MS:(ESI,m / z):563.15[M+H] + ,RT(min):1.184
[0188] Step 2: Synthesis of 5-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-3-fluoropyridin-4-yl]-7-(2-hydroxyethylsulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (Compound 27):
[0189] To a solution of 5-(6-azaspiro[2.5]octan-6-yl)-7-bromo-N-[2-(4,4-difluoropiperidin-1-yl)-3-fluoropyridin-4-yl]-2,3-dihydro-1H-indene-4-carboxamide (30 mg, 0.053 mmol, 1 eq) and 2-hydroxyethanesulfonamide (13.33 mg, 0.106 mmol, 2 eq) in 1,4-dioxane (2 mL) was added cesium carbonate (52.04 mg, 0.159 mmol, 3 eq), bicyclohexyl(3-isopropoxy-2′,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphine (5.69 mg, 0.011 mmole) at room temperature under nitrogen. ol, 0.2eq) and (methanesulfonic acid {dicyclohexyl (3-isopropoxy-2', 4', 6'-triisopropyl-[1,1'-biphenyl]-2-yl) phosphine} (2'-methylamino-1,1'-biphenyl-2-yl) palladium (II) (4.89 mg, 0.005 mmol, 0.1eq). After the addition was complete, the system was stirred at 100 ° C for 1 hour. After the reaction was completed, water (10 mL) was added to quench the reaction and extracted with ethyl acetate (3×10 mL). The organic phases were combined, backwashed with saturated brine (1×10 mL), and dried over anhydrous sodium sulfate. After the obtained mixture was filtered, the filtrate was concentrated under reduced pressure. The crude product was purified by high performance liquid chromatography under the following conditions: Chromatographic column specifications: XBridge BEH Shield RP18 5μm, 30mm*150mm; mobile phase A: water (10mmol / L ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60mL / min; elution gradient: 50% B to 75% B in 8min; elution at 254nm; Rt: 6.9min. The product was 5-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-3-fluoropyridin-4-yl]-7-(2-hydroxyethylsulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (17.1mg, 52.75%).
[0190] MS:(ESI,m / z):608.45[M+H] + ,RT(min):1.736
[0191] 1H NMR(400MHz,DMSO-d6)δ11.50(s,1H),9.33(s,1H),8.00–7.85(m,2H),7.1 8(s,1H),4.99(s,1H),3.78(t,J=6.5Hz,2H),3.54(t,J=5.7Hz,4H),3.30( d,J=6.4Hz,2H),3.10(t,J=7.5Hz,2H),2.94(t,J=5.2Hz,4H),2.85(t,J=7 .5Hz,2H),2.14–2.01(m,4H),2.01–1.91(m,2H),1.46(s,4H),0.32(s,4H).
[0192] Example 6
[0193] 5-{6-azaspiro[2.5]octan-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)-5-fluoropyridin-2-yl]-7-(2-hydroxyethanesulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (Compound 28)
[0194] The first step is the synthesis of 5-{6-azaspiro[2.5]octane-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-5-fluoropyridin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (compound 28-2):
[0195] Under nitrogen, 6-(4,4-difluoropiperidin-1-yl)-5-fluoropyridin-2-amine (23.77 mg, 0.103 mmol, 1.2 eq), tetramethylchloroformamidine hexafluorophosphate (96.13 mg, 0.344 mmol, 4 eq), and N-methylimidazole (70.33 mg, 0.860 mmol, 10 eq) were added to a solution of 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-2,3-dihydro-1H-indene-4-carboxylic acid (30 mg, 0.086 mmol, 1 eq) in dichloromethane (1 mL) at room temperature. The mixture was stirred at 80°C for 1 hour. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (3 × 20 mL). The organic phases were combined, backwashed with saturated brine (1 × 20 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (8:1) to give 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-5-fluoropyridin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (50 mg, 91.17%).
[0196] MS:(ESI,m / z):562.65[M+H] + ,RT(min):1.806
[0197] Step 2: Synthesis of 5-{6-azaspiro[2.5]octan-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)-5-fluoropyridin-2-yl]-7-(2-hydroxyethanesulfonyl)-2,3-dihydro-1H-indene-4-carboxamide (Compound 28):
[0198] To a solution of 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-5-fluoropyridin-2-yl]-2,3-dihydro-1H-indene-4-carboxamide (50 mg, 0.089 mmol, 1 eq) in 1,4-dioxane (2 mL) was added methanesulfonic acid {biscyclohexyl(3-isopropoxy-2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphane}(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (8.15 mg, 0.009 mmol, 0.1 eq), biscyclohexyl(3-isopropoxy-2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphane}(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (8.15 mg, 0.009 mmol, 0.1 eq), biscyclohexyl(3-isopropoxy-2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphane}(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (8.15 mg, 0.009 mmol, 0.1 eq), biscyclohexyl(3-isopropoxy-2' ,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphine (9.49 mg, 0.018 mmol, 0.2 eq), cesium carbonate (86.74 mg, 0.267 mmol, 3 eq) and 2-hydroxyethane-1-sulfonamide (16.66 mg, 0.134 mmol, 1.5 eq). The reaction solution was heated to 100°C and stirred for 1 hour. The reaction solution was cooled to room temperature and extracted with ethyl acetate (3×10 mL). The organic phases were combined and backwashed with saturated brine (2×10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative high-performance liquid chromatography under the following conditions: Chromatographic column specifications: YMC Triart C18 EXRs 5μm, 30mm*150mm; mobile phase A: water (0.1% ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60mL / min; elution gradient: 60% B to 85% B in 8min; detection wavelength: 220nm; retention time (min): 7.8. 5-{6-azaspiro[2.5]octan-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)-5-fluoropyridin-2-yl]-7-(2-hydroxyethanesulfonamido)-2,3-dihydro-1H-indene-4-carboxamide (10.08mg, 18.69%) was obtained.
[0199] MS:(ESI,m / z):608.45[M+H] + ,RT(min):1.863
[0200] 1H NMR: (400MHz, DMSO-d6) δ12.43(s,1H),9.34(s,1H),7.78–7.68(m,1H),7.62–7.52(m,1H),7.23(s,1H),4.97(s,1H),3.77(s,2H),3.64–3.48( m,4H),3.30(s,2H),3.25–3.18(m,2H),3.01–2.89(m,4H),2.88–2.79( m,2H),2.18–2.03(m,4H),2.02–1.91(m,2H),1.63(s,4H),0.35(s,4H).
[0201] Example 7
[0202] 7-{6-azaspiro[2.5]octan-6-yl}-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-5-(2-hydroxyethanesulfonamido)imidazo[1,2-a]pyridine-8-carboxamide (Compound 29)
[0203] The first step is the synthesis of methyl 5,7-dichloroimidazo[1,2-a]pyridine-8-carboxylate (compound 29-3):
[0204] Under nitrogen, a solution of 2-bromo-1,1-dimethoxyethane (3.2 g, 19.001 mmol, 2.1 eq) in hydrobromic acid (20 mL) was stirred at room temperature for 30 minutes. Ethanol (15 mL) was then added, followed by the addition of sodium bicarbonate (5.3 g, 63.336 mmol, 7 eq) and methyl 2-amino-4,6-dichloropyridine-3-carboxylate (2 g, 9.048 mmol, 1 eq). The reaction mixture was heated to 60°C and stirred for 1 hour. The reaction mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate (3 × 80 mL). The organic phases were combined, backwashed with saturated brine (2 × 80 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (3:1) to give methyl 5,7-dichloroimidazo[1,2-a]pyridine-8-carboxylate (1.5 g, 67.65%).
[0205] MS:(ESI,m / z):244.08[M+H] + ,RT(min):0.886
[0206] Step 2: Synthesis of 5,7-dichloroimidazo[1,2-a]pyridine-8-carboxylic acid (Compound 29-4):
[0207] To a mixture of methyl 5,7-dichloroimidazo[1,2-a]pyridine-8-carboxylate (680 mg, 2.775 mmol, 1 eq) in water (5 mL) and tetrahydrofuran (5 mL) was added lithium hydroxide (199.37 mg, 8.325 mmol, 3 eq) at room temperature. The mixture was stirred at room temperature for 16 hours. The reaction mixture was acidified to pH 6 with 1N hydrochloric acid solution. The resulting mixture was concentrated to give crude 5,7-dichloroimidazo[1,2-a]pyridine-8-carboxylic acid (1.2 g).
[0208] MS:(ESI,m / z):230.90[M+H] + ,RT(min):0.498
[0209] Step 3: Synthesis of 5,7-dichloro-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]imidazo[1,2-a]pyridine-8-carboxamide (Compound 29-5):
[0210] Under nitrogen, 6-(4,4-difluoropiperidin-1-yl)-4-methylpyrimidin-2-amine (944.33 mg, 4.156 mmol, 1.2 eq), N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (3886.32 mg, 13.852 mmol, 4 eq), and N-methylimidazole (2843.13 mg, 34.630 mmol, 10 eq) were added to a solution of 5,7-dichloroimidazo[1,2-a]pyridine-8-carboxylic acid (800 mg, 3.463 mmol, 1 eq) in dichloromethane (4 mL) at room temperature. The reaction was stirred at room temperature for 2 hours. The reaction mixture was extracted with ethyl acetate (3 × 50 mL). The combined organic phases were backwashed with saturated brine (1 × 50 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (5:1) to give 5,7-dichloro-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]imidazo[1,2-a]pyridine-8-carboxamide (350 mg, 22.91%).
[0211] MS:(ESI,m / z):441.25[M+H] + ,RT(min):1.198
[0212] Step 4 Synthesis of ethyl 2-[(7-chloro-8-{[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]carbamoyl}imidazo[1,2-a]pyridin-5-yl)sulfamoyl]acetate (Compound 29-7):
[0213] To a solution of 5,7-dichloro-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]imidazo[1,2-a]pyridine-8-carboxamide (300 mg, 0.680 mmol, 1 eq) in 1,4-dioxane (5 mL) was added ethyl 2-sulfamoyl acetate (170.49 mg, 1.020 mmol, 1.5 eq), (methanesulfonic acid {biscyclohexyl(3-isopropoxy-2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine}(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (62.45 mg, 0.068 mmol, 0.1 eq), bicyclohexyl(3-isopropoxy-2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine}(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (75.87 mg, 0.068 mmol, 0.1 eq), and 1,4-dioxane (5 mL) were added ethyl 2-sulfamoyl acetate (170.49 mg, 1.020 mmol, 1.5 eq). ]-2-yl)phosphane (72.72 mg, 0.136 mmol, 0.2 eq) and cesium carbonate (664.54 mg, 2.040 mmol, 3 eq). The reaction mixture was heated to 100°C for 1 hour. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (3 × 40 mL). The organic phases were combined, backwashed with saturated brine (1 × 50 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (5:1) to obtain ethyl 2-[(7-chloro-8-{[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]carbamoyl}imidazo[1,2-a]pyridin-5-yl)sulfamoyl]acetate (150 mg, 38.57%).
[0214] MS:(ESI,m / z):572.45[M+H] + ,RT(min):1.094
[0215] Step 5 Synthesis of ethyl 2-[(7-{6-azaspiro[2.5]octane-6-yl}-8-{[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]carbamoyl}imidazo[1,2-a]pyridin-5-yl]sulfamoyl]acetate (Compound 29-8):
[0216] Under nitrogen, 6-azaspiro[2.5]octane (34.99 mg, 0.315 mmol, 1.5 eq) and triethylamine (63.69 mg, 0.630 mmol, 3 eq) were added to a solution of ethyl 2-[(7-chloro-8-{[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]carbamoyl}imidazo[1,2-a]pyridin-5-yl)sulfamoyl]ethyl ester (120 mg, 0.210 mmol, 1 eq) in tert-butanol (1 mL) at room temperature. The reaction mixture was heated to 100°C and stirred for 2 days. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (3 × 20 mL). The organic phases were combined, backwashed with saturated brine (2 × 20 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (1:1) to give ethyl 2-[(7-{6-azaspiro[2.5]octan-6-yl}-8-{[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]carbamoyl}imidazo[1,2-a]pyridin-5-yl]sulfamoyl]acetate (60 mg, 44.22%).
[0217] MS:(ESI,m / z):647.45[M+H] + ,RT(min):1.240
[0218] Step 6: Synthesis of 7-{6-azaspiro[2.5]octan-6-yl}-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-5-(2-hydroxyethanesulfonyl)imidazo[1,2-a]pyridine-8-carboxamide (Compound 29):
[0219] Under nitrogen protection, lithium aluminum hydride (5.28 mg, 0.140 mmol, 1.5 eq) was added to a solution of ethyl 2-[(7-{6-azaspiro[2.5]octan-6-yl}-8-{[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]carbamoyl}imidazo[1,2-a]pyridin-5-yl]sulfamoyl]ethyl ester (60 mg, 0.093 mmol, 1 eq) in tetrahydrofuran (3.00 mL) at 0°C and the reaction was stirred at room temperature for 30 minutes. The reaction solution was quenched with sodium sulfate decahydrate at 0°C. Filtered and concentrated under reduced pressure. The crude product was purified by high performance liquid chromatography under the following conditions (chromatographic column specifications: XBridge BEH Shield RP18 5μm, 30mm*150mm; mobile phase A: water (10mmol / L sodium bicarbonate), mobile phase B: acetonitrile; flow rate: 60ml / min; elution gradient: 40%B to 60%B in 10min; detection wavelength: 254nm / 220nm; retention time (min): 8.33). 7-{6-azaspiro[2.5]octan-6-yl}-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-5-(2-hydroxyethanesulfonamido)imidazo[1,2-a]pyridine-8-carboxamide (1.8mg, 3.21%) was obtained.
[0220] MS:(ES,m / z):605.45[M+H] + ,RT(min):1.559.
[0221] 1 H NMR: (400MHz, DMSO-d6) δ12.31(s,1H),11.77(s,1H),7.83(s,1H),7.48-7.28(m,2H),7.11(s,1H),4.15(s, 2H),3.98(s,4H),3.70-3.35(m,4H),3.32-3.01(m,4H),2.55(s,2H),2.38(s,3H),1.98(s,4H),0.43(s,4H).
[0222] Example 8
[0223] N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-5-(2-hydroxyethanesulfonamido)-7-{6-azaspiro[2.5]octan-6-yl}-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide (Compound 30)
[0224] The first step is the synthesis of methyl 4,6-dichloro-2-[[(E)-(hydroxyamino)methylene]amino]pyridine-3-carboxylate (Compound 30-2):
[0225] To a solution of methyl 2-amino-4,6-dichloropyridine-3-carboxylate (3 g, 13.572 mmol, 1 eq) in isopropanol (60.00 mL) was added N,N-dimethylformamide dimethyl acetal (2.18 mL, 16.286 mmol, 1.20 eq) at room temperature under nitrogen. The mixture was heated to 70°C and stirred for 3 hours. After cooling to room temperature, hydroxylamine hydrochloride (1.13 g, 16.286 mmol, 1.2 eq) was added and stirred for 3 hours at room temperature. The mixture was filtered, the filter cake collected, and washed with isopropanol (3 × 50 mL). This afforded the product, methyl 4,6-dichloro-2-[[(E)-(hydroxyamino)methylene]amino]pyridine-3-carboxylate (1.5 g, 41.85%).
[0226] MS:(ESI,m / z):264.10[M+H] + ,RT(miN):0.949.
[0227] Step 2: Synthesis of methyl 5,7-dichloro-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylate (Compound 30-3):
[0228] Under nitrogen, at 0°C, a solution of trifluoroacetic anhydride (1.79 g, 8.521 mmol, 1.5 eq) in acetonitrile (5 mL) was added dropwise to a solution of methyl 4,6-dichloro-2-[[(E)-(hydroxyamino)methylene]amino]pyridine-3-carboxylate (1.5 g, 5.681 mmol, 1 eq) in acetonitrile (10 mL). The mixture was heated to room temperature and stirred for 4 hours. The reaction solution was concentrated under reduced pressure. Neutralized with saturated aqueous sodium bicarbonate to pH 7. Extracted with dichloromethane (3 × 20 mL). The organic phases were combined, backwashed with saturated brine (1 × 20 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (1:2) to give methyl 5,7-dichloro-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylate (1.1 g, 77.13%).
[0229] MS:(ESI,m / z):246.20[M+H] + ,RT(min):0.828.
[0230] Step 3: Synthesis of methyl 7-chloro-5-{[(2,4-dimethoxyphenyl)methyl]amino}-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylate (Compound 30-5):
[0231] Under nitrogen, triethylamine (740.29 mg, 7.317 mmol, 3 eq) was added to a solution of methyl 5,7-dichloro-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylate (600 mg, 2.439 mmol, 1 eq) in tert-butanol (6 mL) at room temperature. After stirring for 2 minutes, 3,4-dimethoxybenzylamine (16.31 mg, 0.097 mmol, 1.2 eq) was added dropwise at room temperature. The mixture was heated to 60°C and stirred for 2 hours. The reaction mixture was cooled to room temperature, diluted with water (20 mL), and extracted with ethyl acetate (3 × 20 mL). The organic phases were combined, backwashed with saturated brine (1 × 20 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (1:3) to give methyl 7-chloro-5-{[(2,4-dimethoxyphenyl)methyl]amino}-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylate (700 mg, 68.56%).
[0232] MS:(ESI,m / z):377.35[M+H] + ,RT(min):1.062.
[0233] Step 4 Synthesis of 7-chloro-5-{[(2,4-dimethoxyphenyl)methyl]amino}-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylic acid (Compound 30-6):
[0234] Under nitrogen, lithium hydroxide (114.41 mg, 4.776 mmol, 3 eq) was added portionwise to a solution of methyl 7-chloro-5-{[(2,4-dimethoxyphenyl)methyl]amino}-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylate (600 mg, 1.592 mmol, 1 eq) in methanol (2 mL), tetrahydrofuran (2 mL), and water (2 mL) at room temperature. The mixture was heated to 60°C and stirred for 1 hour. The reaction mixture was acidified to pH 4 with 1N hydrochloric acid. A white solid precipitated, which was collected by filtration to yield 1 g of crude product.
[0235] MS:(ESI,m / z):363.60[M+H] + ,RT(min):1.000.
[0236] Step 5 Synthesis of 7-chloro-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-5-{[(2,4-dimethoxyphenyl)methyl]amino}-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide (Compound 30-7):
[0237] Under nitrogen, to a solution of 7-chloro-5-{[(2,4-dimethoxyphenyl)methyl]amino}-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylic acid (500 mg, 1.378 mmol, 1 eq) and 6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-amine (375.87 mg, 1.654 mmol, 1.2 eq) in N,N-dimethylformamide (10 mL) were added portionwise N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (1.5 g, 5.512 mmol, 4 eq) and N-methylimidazole (1.1 g, 13.780 mmol, 10 eq) at room temperature. The mixture was heated to 60°C and stirred for 1 hour. The reaction solution was cooled to room temperature, diluted with water (20 mL), and extracted with dichloromethane (3 × 20 mL). The organic phases were combined, backwashed with saturated brine (1 × 20 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with petroleum ether / ethyl acetate (3:1) to obtain 7-chloro-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-5-{[(2,4-dimethoxyphenyl)methyl]amino}-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide (500 mg, 60.25%).
[0238] MS:(ESI,m / z):572.50[M+H] + ,RT(min):1.370.
[0239] Step 6 Synthesis of 7-{6-azaspiro[2.5]octan-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-5-{[(2,4-dimethoxyphenyl)methyl]amino}-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide (Compound 30-8):
[0240] Under nitrogen, 6-azaspiro[2.5]octane hydrochloride (309.75 mg, 2.098 mmol, 2 eq) was added portionwise to a solution of 7-chloro-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-5-{[(2,4-dimethoxyphenyl)methyl]amino}-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide (600 mg, 1.049 mmol, 1 eq) and triethylamine (318.43 mg, 3.147 mmol, 3 eq) in tert-butanol (10 mL) at room temperature. The mixture was heated to 120°C and stirred for 2 hours. The reaction mixture was cooled to room temperature and diluted with water (10 mL). Extraction was performed with dichloromethane (3 × 10 mL). The organic phases were combined, backwashed with saturated brine (1 × 10 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using dichloromethane / methanol (10:1) to obtain compound 30-8 (445 mg, 62.32%).
[0241] MS:(ESI,m / z):647.60[M+H] + ,RT(min):1.172.
[0242] Step 7 Synthesis of 5-amino-7-{6-azaspiro[2.5]octane-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide (Compound 30-9):
[0243] Under nitrogen, a solution of compound 30-8 (410 mg, 0.634 mmol, 1 eq) in trifluoroacetic acid (5 mL, 67.315 mmol, 106.18 eq) was stirred at 60°C for 1 hour. The reaction mixture was cooled to room temperature, and the resulting residue was concentrated under reduced pressure. The product was basified with saturated aqueous sodium bicarbonate to pH 8. The product was extracted with ethyl acetate (3 x 20 mL). The combined organic phases were backwashed with saturated brine (1 x 20 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by reverse-phase column chromatography using the following conditions: column specifications (C18 column), mobile phase: water and acetonitrile, gradient from 0% to 80% over 10 minutes, UV detection at 254 nm. Compound 30-9 (310 mg, 88.63%) was obtained.
[0244] MS:(ESI,m / z):497.30[M+H] + ,RT(min):1.410.
[0245] Step 8 Synthesis of ethyl 2-[(7-{6-azaspiro[2.5]octane-6-yl}-8-{[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]carbamoyl}-[1,2,4]triazolo[1,5-a]pyridin-5-yl)sulfamoyl]acetate (Compound 30-11):
[0246] Under nitrogen, ethyl 2-(chlorosulfonyl)acetate (75.16 mg, 0.402 mmol, 2 eq) was added dropwise to a solution of compound 30-9 (100 mg, 0.201 mmol, 1 eq) and triethylamine (61.14 mg, 0.603 mmol, 3 eq) in dichloromethane (3 mL) at 0°C. The mixture was allowed to warm to room temperature and stirred for 2 hours. The mixture was diluted with water (10 mL) and extracted with dichloromethane (3 × 10 mL). The combined organic phases were backwashed with saturated brine (1 × 10 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase column chromatography using a C18 column, mobile phase consisting of water and acetonitrile, with a gradient from 10% to 70% over 10 minutes, and UV detection at 254 nm. Compound 30-11 (80 mg, 61.43%) was obtained.
[0247] MS:(ESI,m / z):647.30[M+H] + ,RT(min):1.100.
[0248] Step 9 Synthesis of N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-5-(2-hydroxyethanesulfonyl)-7-{6-azaspiro[2.5]octan-6-yl}-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide (Compound 30):
[0249] Under nitrogen, a solution of lithium aluminum tetrahydride in tetrahydrofuran (6.16 mg, 0.162 mmol, 1.5 eq) was added dropwise to a solution of compound 30-11 (70 mg, 0.108 mmol, 1 eq) in tetrahydrofuran (3 mL) at 0°C. After the addition was complete, the system was stirred at 0°C for 1 hour. The reaction mixture was quenched with ice water at 0°C. The reaction mixture was extracted with ethyl acetate (3 × 10 mL). The combined organic phases were backwashed with saturated brine (1 × 10 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by HPLC using the following conditions: SuNfire C18 5μm column, 30mm x 150mm; mobile phase A: water (0.05% formic acid), mobile phase B: acetonitrile; flow rate: 60mL / min; elution gradient: 35% B to 68% B in 8min; elution rate: 254nm / 220nm; Rt: 7.42min. Compound 30 (23.73mg, 35.42%) was obtained.
[0250] MS:(ESI,m / z):605.20[M+H] + ,RT(min):1.720.
[0251] 1 H NMR (400MHz, DMSO-d6) δ14.04(s,1H),11.77(s,1H),8.96(s,1H),7.51(s,1H),6.87(s,1H),6.59(s,1H),4.96(s,1H),3.83(t,J=6. 6Hz,2H),3.72(t,J=6.1Hz,4H),3.21(t,J=6.7Hz,2H),3.10(s,4H),2.27(s,3H),1.97(t,J=15.6Hz,4H),1.72(s,4H),0.39(s,4H).
[0252] Example 9
[0253] 5-{6-Azaspiro[2.5]octan-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-7-(2-hydroxyethanesulfonamido)-3-methyl-1,3-benzodiazole-4-carboxamide (Compound 31)
[0254] The first step is the synthesis of methyl 4-bromo-2,6-difluoro-3-nitrobenzoate (compound 31-2):
[0255] Under nitrogen, nitric acid (1.25 mL) was added to a solution of methyl 4-bromo-2,6-difluorobenzoate (5 g, 20 mmol, 1 eq) in sulfuric acid (17 mL) at room temperature. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with water at room temperature and extracted with dichloromethane (3 × 100 mL). The organic phases were combined and backwashed with saturated brine (2 × 120 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain crude methyl 4-bromo-2,6-difluoro-3-nitrobenzoate (6.01 g).
[0256] 1 H NMR: (400MHz, DMSO-d6) δ8.11 (dd, J=9.5, 2.1Hz, 1H), 3.93 (s, 3H).
[0257] Step 2: Synthesis of methyl 4-bromo-6-fluoro-2-methylamino-3-nitrobenzoate (Compound 31-3):
[0258] Methylamine (472 mg, 15 mmol, 1.5 eq) was added to a solution of methyl 4-bromo-2,6-difluoro-3-nitrobenzoate (3 g, 10 mmol, 1 eq) in methanol (30 mL) at room temperature under nitrogen atmosphere. The reaction mixture was stirred at 60°C for 16 hours. The reaction mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate (3 × 80 mL). The combined organic phases were backwashed with saturated brine (2 × 80 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford methyl 4-bromo-6-fluoro-2-methylamino-3-nitrobenzoate (2.21 g, 71%).
[0259] MS:(ESI,m / z):306.85[M+H] + ,RT(min):1.180
[0260] Step 3: Synthesis of methyl 6-{6-azaspiro[2.5]octane-6-yl}-4-bromo-2-methylamino-3-nitrobenzoate (Compound 31-4):
[0261] To a solution of methyl 4-bromo-6-fluoro-2-methylamino-3-nitrobenzoate (500 mg, 1.6 mmol, 1 eq) in tert-butanol (15 mL) under nitrogen was added 6-azaspiro[2.5]octane hydrochloride (217 mg, 2 mmol, 1.2 eq) and triethylamine (824 mg, 8 mmol, 5 eq) at room temperature. The reaction mixture was heated to 100°C and stirred for 16 hours. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (3 × 30 mL). The organic phases were combined and backwashed with saturated brine (2 × 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to obtain methyl 6-{6-azaspiro[2.5]octan-6-yl}-4-bromo-2-methylamino-3-nitrobenzoate (460 mg, 71%).
[0262] MS:(ESI,m / z):398.35[M+H] + ,RT(min):1.380
[0263] Step 4: Synthesis of methyl 5-{6-azaspiro[2.5]octane-6-yl}-7-bromo-3-methyl-1,3-benzodiazole-4-carboxylate (Compound 31-6):
[0264] Under nitrogen protection, trimethyl orthoformate (3.5 g, 33 mmol, 30 eq), zinc powder (433 mg, 6.6 mmol, 6 eq), lithium bromide (115 mg, 1.3 mmol, 1.2 eq) and formic acid (508 mg, 11 mmol, 10 eq) were added to a solution of methyl 6-{6-azaspiro[2.5]octan-6-yl}-4-bromo-2-methylamino-3-nitrobenzoate (440 mg, 1.1 mmol, 1 eq) in ethanol (3 mL) at room temperature. After the addition was complete, the reaction was stirred at room temperature for 1 hour. The mixture was quenched with water, extracted with ethyl acetate (3×30 mL), and the organic phases were combined and backwashed with saturated brine (2×30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 5:1) to give methyl 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-3-methyl-1,3-benzodiazole-4-carboxylate (190 mg, 45.5%).
[0265] MS:(ESI,m / z):378.30[M+H] + ,RT(min):1.193
[0266] Step 5 Synthesis of 5-{6-azaspiro[2.5]octane-6-yl}-7-bromo-3-methyl-1,3-benzodiazole-4-carboxylic acid (Compound 31-7):
[0267] Under nitrogen protection, lithium hydroxide (31.7 g, 1.3 mmol, 5 eq), distilled water (2 mL) and methanol (2 mL) were added to a solution of methyl 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-3-methyl-1,3-benzodiazole-4-carboxylate (100 mg, 0.3 mmol, 1 eq) in tetrahydrofuran (2 mL) at room temperature. The reaction solution was heated to 60°C and stirred for 72 hours. The reaction solution was extracted with ethyl acetate (2×10 mL), the aqueous phase was collected, the pH was adjusted to 6 with 1 M dilute hydrochloric acid, extracted with ethyl acetate (2×10 mL), the organic phases were combined, and backwashed with saturated brine (2×10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-3-methyl-1,3-benzodiazole-4-carboxylic acid (101 mg, 105%).
[0268] MS:(ESI,m / z):364.30[M+H] + ,RT(min):0.763
[0269] Step 6 Synthesis of 5-{6-azaspiro[2.5]octane-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-3-methyl-1,3-benzodiazole-4-carboxamide (Compound 31-8):
[0270] Under nitrogen, to a solution of 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-3-methyl-1,3-benzodiazole-4-carboxylic acid (60 mg, 0.16 mmol, 1 eq) in dichloromethane (4 mL) were added 6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-amine (112 mg, 0.5 mmol, 3 eq), N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (185 mg, 0.7 mmol, 4 eq), and N-methylimidazole (135 mg, 1.7 mmol, 10 eq) at room temperature. The reaction mixture was heated to 60°C and stirred for 1 hour. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (3 × 10 mL). The organic phases were combined, backwashed with saturated brine (2 × 10 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to give 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-3-methyl-1,3-benzodiazole-4-carboxamide (72 mg, 76%).
[0271] MS:(ESI,m / z):573.30[M+H] +,RT(min):1.392
[0272] Step 7 Synthesis of 5-{6-azaspiro[2.5]octane-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-7-(2-hydroxyethanesulfonamido)-3-methyl-1,3-benzodiazole-4-carboxamide (Compound 31):
[0273] To a solution of 5-{6-azaspiro[2.5]octan-6-yl}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-3-methyl-1,3-benzodiazole-4-carboxamide (100 mg, 0.17 mmol, 1 eq) in 1,4-dioxane (1 mL) was added 2-hydroxyethanesulfonamide (26 mg, 0.2 mmol, 1.2 eq), methanesulfonic acid {biscyclohexyl[3-isopropoxy-2',4',6'-triisopropyl]-1,3-benzodiazole-4-carboxamide}-7-bromo-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-3-methyl ... Propyl-(1,1′-biphenyl)-2-yl]phosphane}(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (16.02 mg, 0.017 mmol, 0.1 eq), bicyclohexyl(3-isopropoxy-2′,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphane (18.65 mg, 0.035 mmol, 0.2 eq), cesium carbonate (170.44 mg, 0.522 mmol, 3 eq), the reaction solution was heated to 100°C and stirred for 1 hour. The reaction solution was cooled to room temperature and extracted with ethyl acetate (3×10 mL). The organic phases were combined and backwashed with saturated brine (2×10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative high performance liquid chromatography to give 5-{6-azaspiro[2.5]octan-6-yl}-N-[6-(4,4-difluoropiperidin-1-yl)-4-methylpyridin-2-yl]-7-(2-hydroxyethanesulfonamido)-3-methyl-1,3-benzodiazole-4-carboxamide (7.08 mg, 6.3%).
[0274] MS:(ESI,m / z):618.70[M+H] + ,RT(min):1.903
[0275] 1H NMR: (400MHz, DMSO-d6) δ10.73(s,1H),9.15(s,1H),8.18(s,1H),7.42(s,1H),7.15(s,1H),6.57(s,1H),5.05(s,1H),3.83(d,J=6.6Hz,2H),3.8 0(d,J=3.9Hz,3H),3.69(t,J=5.5Hz,4H),3.45(t,J=6.6Hz,2H),2.96(t, J=5.2Hz,4H),2.29(s,3H),2.05–1.85(m,4H),1.45(s,4H),0.29(s,4H).
[0276] Biological evaluation
[0277] Test Example 1
[0278] Test Name: Imaging-based Nuclear Count Analysis (NCA) in OVCAR-3 cells
[0279] Day 0 Compound Dilution and Treatment
[0280] a) Final tested concentrations of AM-5308 were: 10000, 3333.3, 1111.1, 370.3, 123.4, 41.1, 13.7, 4.5, 1.5, and 0.5 nM.
[0281] b) The final test concentrations of the test compounds are: 10000, 3333.3, 1111.1, 370.3, 123.4, 41.1, 13.7, 4.5, 1.5, and 0.5 nM.
[0282] c) The cells were cultured in a 37°C, 5% CO2 incubator for 4 days.
[0283] d) The DMSO concentration was 0.1%.
[0284] On day 1, cells were seeded into 384-well cell culture plates.
[0285] a) When the cell confluence reaches 80%-90%, treat the cells.
[0286] b) Resuspend the cells in culture medium, then count and dilute the cells to the desired density.
[0287] c) Add 30 μL / well of the cell suspension containing appropriate cells to a 384-well plate: 600 cells / well.
[0288] Day 4 testing
[0289] a) Add 30 μL of 8% fixative (final concentration 4%) and incubate the plate at room temperature for 30 minutes.
[0290] b) Centrifuge the plate at 1000 RPM for 30 seconds.
[0291] c) Wash twice with 60 μl / well PBS.
[0292] d) After fixation, cells were permeabilized and stained in 60 μL of wash buffer (1% BSA, 0.2% Triton X-100, 1X PBS) containing 2 μg / mL Hoechst 33342 DNA dye.
[0293] e) Seal the plate and incubate at room temperature in the dark for 1 hour.
[0294] f) Wash three times with PBS.
[0295] g) Add 50 μL PBS / well and scan the plate using HCS.
[0296] h) Data collection and detection
[0297] Data Analysis
[0298] Inhibition rate (%) = 100-(compound well reading value-low reading control well reading value) / (high reading control well reading value-low reading control well reading value)*100
[0299] High-reading control wells: cells plus 30 nL DMSO; low-reading control wells: 10 μM AM-5308.
[0300] IC was calculated using GraphPad Prism 8 software. 50 (nM) and draw the effect-dose curve of the compound.
[0301] Table 1 Biological activity data of the compounds of this application
[0302] Test Example 2
[0303] Test Name: ADP-Glo TM Kinase assays
[0304] Steps:
[0305] 1) Prepare 1× reaction buffer.
[0306] 2) Transfer 100 nL of the diluted compound stock solution to each well of the reaction plate using an Echo 655. The final DMSO concentration is 1%.
[0307] 3) Seal the reaction plate with sealing film and centrifuge at 1000g for 1 minute.
[0308] 4) Prepare 2× enzyme solution using 1× reaction buffer.
[0309] 5) Add 5 μL of 2× enzyme solution to each well of the reaction plate. Seal the plate with film and centrifuge at 1000 g for 1 minute. Incubate at room temperature for 15 minutes.
[0310] 6) Prepare 2× ATP solution using 1× reaction buffer.
[0311] 7) Add 5 μL of 2× ATP solution to the reaction plate and centrifuge at 1000 g for 1 minute to start the reaction.
[0312] 8) React at room temperature for 60 minutes.
[0313] 9) Add 10 μL of ADP Glo reagent, centrifuge at 1000 g for 1 minute, and incubate at room temperature for 60 minutes.
[0314] 10) Add 20 μL of kinase assay reagent, centrifuge at 1000 g for 1 minute, and incubate at room temperature for 60 minutes.
[0315] 11) Centrifuge at 1000g for 1 minute.
[0316] 12) Read the luminescence signal on Envision 2104.
[0317] Data Analysis:
[0318] The inhibition percentage is calculated as follows: %inhibition=100-(Signal cmpd -Signal Ave_PC ) / (Signal Ave_VC -Signal Ave_PC )×100
[0319] Signal cmpd : Average value of test compounds on the reaction plate.
[0320] Signal Ave_PC : Average value of positive control on the reaction plate.
[0321] Signal Ave_VC : Average value of negative control on the reaction plate.
[0322] Computing IC 50 And fitting compound dose-effect curve:
[0323] GraphPad 8.0 was used to obtain the IC values of the compounds using a nonlinear fitting formula. 50 .
[0324] 3) Quality control
[0325] Z factor>0.5;S / B>2.
[0326] Table 2 Enzyme activity data of the compounds of the present application
[0327] Test Example 3 Effect of the Compounds of the Invention on Tumor Regression
[0328] To demonstrate the effect of KIF18A inhibitors on tumor regression, OVCAR-3 cells (ATCC) were selected for the experiment. 5×10 6 OVCAR-3 cells. According to the tumor volume (average tumor volume 150mm 3 Animals were randomly divided into six groups (vehicle group, compound 9 divided into three dose groups of 10, 20, or 30 mg / kg, and AMG650 divided into two dose groups of 15 or 30 mg / kg), with 10 animals per group. Starting from day 28 after tumor inoculation, oral administration was performed once daily. Tumor volume was measured using an electronic vernier caliper (Chengdu Sanhe Measuring Instrument Co., Ltd.). Tumor volume and animal body weight were measured twice weekly (day 28 from the start of the study to day 46 at the end of the study), and the tumor growth inhibition rate of the compound was calculated.
[0329] The formula for calculating tumor volume is: 1 / 2×a×b 2 , where a and b are the length and width of the tumor, respectively.
[0330] The calculation formula of tumor inhibition rate %TGI is: 1-(TV Tn -TV T0 ) / (TV Cn -TV C0 )×100%, TVC is the average tumor volume of the negative control group, and TVT is the average tumor volume of the treatment group.
[0331] Data were plotted using GraphPad Prism software (V9.5.0). Tumor volume and body weight data are presented as the mean ± standard error of the mean. As shown in Figure 1, the TGIs for compound 9 at 10, 20, and 30 mg / kg were 47.35%, 106.60%, and 115.58%, respectively; and for AMG650 at 15 and 30 mg / kg, they were 72.58% and 113.15%, respectively. All doses of compound 9 had no significant effect on body weight changes relative to the vehicle group, indicating no significant toxicity was observed.
[0332] These results demonstrate that compound 9 of the present invention can induce tumor regression in a female nude mouse xenograft model of human hyperserous ovarian cancer OVCAR-3 cells (TP53 mutation, CCNE1 amplification). Compound 9 significantly inhibited tumor growth in subcutaneous OVCAR-3 xenograft mice at doses of 20 and 30 mg / kg. The inhibitory effect of compound 9 at a dose of 20 mg / kg on subcutaneous xenografts in mice was comparable to that of AMG650 at 30 mg / kg.
[0333] As shown in Table 3, compound 9 has a superior tumor-to-blood ratio (the ratio of tumor tissue exposure to plasma exposure) compared to AMG650, indicating that a higher proportion of the drug enters the tumor tissue to exert its effect. Furthermore, compared to AMG650, compound 9's lower absolute exposure may reduce the potential for cumulative toxicity.
[0334] Table 3. Exposure in mouse plasma and tumor tissue
[0335] The above is an exemplary description of the implementation methods of the technical solution of the present invention. It should be understood that the scope of protection of the present invention is not limited to the above implementation methods. Any modifications, equivalent substitutions, improvements, etc. made by those skilled in the art within the spirit and principles of the present invention shall be included in the scope of protection of the claims of this application.
Claims
1. A compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled form, solvate, polymorph, pharmaceutically acceptable salt or prodrug compound: in, A is selected from unsubstituted or optionally substituted with one, two or more R a Replaced Or fused ring group 1; the fused ring group 1 comprises two, three or four independently selected from saturated or partially unsaturated C 3-14 Carbon ring, C 6-14 aromatic ring, 5-14 membered heteroaromatic ring, 3-14 membered heterocyclic ring; each R a the same or different, independently selected from H, OH, halogen, cyano, NH2, NO2, unsubstituted or optionally substituted by one, two or more R a1 Substituted with the following groups: C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl; or, two R attached to the same ring carbon atom a Together with the carbon atoms to which it is connected, it forms a saturated or partially unsaturated C 3-14 Carbon ring; each R a1 the same or different, independently selected from H, OH, halogen, cyano, NH2, NO2, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl; X1, X2, X3 are the same or different and are independently selected from N or CR0; R0 is selected from H, halogen, cyano, C 1-12 Alkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, cyano C 1-12 alkoxy; B is selected from unsubstituted or optionally substituted with one, two or more R b Substituted with the following groups: C 1-12 Alkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, cyano C 1-12 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkyloxy, C 3-12 Cycloalkylthio, 3-14 membered heterocyclic group; each R b The same or different, independently selected from halogen, cyano, C 1-12 Alkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, cyano C 1-12 alkoxy; Ring G is selected from unsubstituted or optionally substituted with one, two or more R g The substituted fused ring group 2 is formed by condensing ring G1 and ring G2; ring G1 is selected from C 6-14 aromatic ring, 5-14 membered heteroaromatic ring, 3-14 membered heterocyclic ring; Ring G2 is selected from C 3-14 Carbon ring, C 6-14 Aromatic ring, 5-14 membered heteroaromatic ring, 3-14 membered heterocyclic ring; M and E are preferably attached to ring G1; each R g The same or different, independently selected from halogen, cyano, C 1-12 Alkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, cyano C 1-12 alkoxy; E is selected from unsubstituted or optionally substituted with one, two or more R e Substituted with the following groups: -NH-S(=O)2-R e1 、-S(=O)2-NH-R e2 、-S(=O)(=NH)-R e3 、-N(R e4 )(R e5 ), 3-14 membered heterocyclic group; each R e The same or different, independently selected from OH, halogen, cyano, C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, cyano C 1-12 Alkyl, cyano C 1-12 Alkoxy, -N(R e6 )(R e7 ); R e1 、R e2 、R e3 、R e4 、R e5 、R e6 、R e7 The same or different, independently selected from H, C 1-12 Alkyl, C 1-12 Alkoxy, hydroxy C 1-12 Alkyl, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, cyano C 1-12 Alkyl, cyano C 1-12 Alkoxy, C 3-12 Cycloalkyl, 3-14 membered heterocyclic group, C 1-12 Alkoxy-C 1-12 alkyl; M is selected from unsubstituted or optionally substituted with one, two or more R m Substituted with the following groups: C 3-12 Cycloalkyl, C 3-12 Cycloalkenyl, 3-14 membered heterocyclic group; each R m The same or different, independently selected from halogen, cyano, C 1-12 Alkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, C 1-12 Alkoxy, cyano C 1-12 Alkoxy.
2. The compound according to claim 1, characterized in that A is selected from unsubstituted or optionally substituted with one, two or more R a Replaced Or fused ring group 1; the fused ring group 1 comprises two, three or four independently selected from saturated or partially unsaturated C 3-8 Carbon ring, C 6-10 aromatic ring, 5-10 membered heteroaromatic ring, 3-8 membered heterocyclic ring; each R a the same or different, independently selected from H, OH, halogen, cyano, NH2, NO2, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano C 1-6 Alkyl, cyano C 1-6 Alkoxy, C 3-8 Cycloalkyl-C 1-6 Alkoxy; or, two R attached to the same ring carbon atom a Together with the carbon atoms to which it is connected, it forms a saturated or partially unsaturated C 3-8 carbon ring; Preferably, A is selected from Wherein, T is selected from CH2, CH, NH, NR a or O; Z is selected from CH2, CH, NH, NR a or O; X is selected from N or CH; n is selected from 0, 1, 2, 3, 4 or 5; p and q are independently selected from 0, 1, 2, and 3, and p and q are not 0 at the same time; r and s are independently selected from 0, 1, 2, and 3, and r and s are not 0 at the same time; Preferably, X1 and X2 are the same or different and are independently selected from N or CR0; Preferably, X1 and X2 are the same or different and are independently selected from N or CH; Preferably, X2 and X3 are not N at the same time; Preferably, when X1 and X2 are N, X3 is CR0; when X1 is N or CR0, X2 is CR0, X3 is N or CR0; when X1 is N or CR0, X2 is N, X3 is CR0; R0 is selected from H, halogen, C 1-6 alkyl; Preferably, when X1 and X2 are N, X3 is CR0; when X1 is N or CH, X2 is CH, X3 is N or CR0; when X1 is CH, X2 is N, X3 is CR0; when X1 is N, X2 is CR0, X3 is N; R0 is selected from H, C 1-6 alkyl; Preferably, B is selected from C 1-6 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyloxy, 3-8 membered heterocyclic group, halogenated 3-8 membered heterocyclic group; Preferably, B is selected from a halogenated 6-membered N-containing heterocyclic group; for example, a halogenated piperidinyl group; Preferably, B is selected from Preferably, A is selected from unsubstituted or optionally substituted with one, two or more R a Replaced or a fused ring group 1; the fused ring group 1 is composed of two, three, four or more rings selected from a benzene ring, a pyridine ring, an imidazole ring, a piperazine ring, a dihydropyridine ring, a tetrahydropyridine ring, a dihydropyrrole ring, a tetrahydropyrrole ring, a dihydropyran ring, a cyclobutene ring, a cyclopentene ring, a cyclohexene ring, and a cycloheptene ring; Preferably, A is selected from unsubstituted or optionally substituted with one, two or more R a Substituted with the following groups: Preferably, each R a are the same or different and are independently selected from H, OH, F, Cl, cyano, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, cyclopropyl, cyclopropylmethoxy; or, two R attached to the same ring carbon atom a Together with the carbon atoms to which they are connected, they form a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, or a cycloheptane ring; Preferably, A is selected from 3. The compound according to claim 1 or 2, characterized in that Ring G is selected from unsubstituted or optionally substituted with one, two or more R g The substituted fused ring group 2 is formed by condensing ring G1 and ring G2; ring G1 is selected from C 6-10 aromatic ring, 5-10 membered heteroaromatic ring, 5-10 membered heterocyclic ring; Ring G2 is selected from C 3-10 Carbon ring, C 6-10 Aromatic ring, 5-10 membered heteroaromatic ring, 3-10 membered heterocyclic ring; Preferably, ring G1 is selected from a cyclopentene ring, a cyclohexene ring, a dihydrofuran ring, a dihydropyran ring, an imidazole ring, a triazole ring, a benzene ring, a pyridine ring, a dihydropyridine ring, a pyrrole ring, a pyrazole ring, a furan ring, and a thiophene ring; preferably a benzene ring or a pyridine ring; Preferably, ring G2 is selected from a cyclopentene ring, a cyclohexene ring, a dihydrofuran ring, a dihydropyran ring, an imidazole ring, a triazole ring, a benzene ring, a pyridine ring, a pyrrole ring, a pyrazole ring, a furan ring, a thiophene ring, and a methylimidazole ring; Preferably, ring G is selected from 4. The compound according to any one of claims 1 to 3, characterized in that E is selected from unsubstituted or optionally substituted with one or two R e Substituted with the following groups: -NH-S(=O)2-R e1 、-S(=O)2-NH-R e2 、-S(=O)(=NH)-R e3 ; R e1 、R e2 、R e3 The same or different, independently selected from H, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano C 1-6 Alkyl, cyano C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 1-6 Alkoxy-C 1-6 Alkyl; each R e The same or different, independently selected from OH, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano C 1-6 Alkyl, cyano C 1-6 alkoxy; Preferably, E is selected from 5. The compound according to any one of claims 1 to 4, characterized in that M is selected from unsubstituted or optionally substituted with one, two or more R m Substituted C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl or nitrogen-containing 3-8 membered heterocyclic group; each R m the same or different, independently selected from H, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, cyano C 1-6 Alkyl, C 1-6 Alkoxy, cyano C 1-6 Alkoxy; or, two R attached to the same ring carbon atom m Together with the carbon atoms to which it is connected, it forms a saturated or partially unsaturated C 3-8 carbon ring; Preferably, M is selected from unsubstituted or optionally substituted with one, two or more R m Replaced 6. The compound according to any one of claims 1 to 5, characterized in that The compound has the following structure: wherein A, M, E, ring G, ring G1, and ring G2 independently have the definitions described in any one of claims 1 to 5, represents a carbon-carbon single bond or a carbon-carbon double bond; Preferably, the compound represented by formula (I) has the following structure: Among them, B, M, E, ring G, X, Z, T, X1, X2, X3, R a , n, p, q, r, s independently have the definitions in any one of claims 1 to 5; Preferably, the compound represented by formula (I) has the following structure: Among them, B, ring G, X, Z, T, X1, X2, X3, R a , n, r, s, p, q independently have the definitions as described in any one of claims 1 to 5; Preferably, the compound represented by formula (I) has the following structure: wherein A, ring G1, and ring G2 independently have the definitions as described in any one of claims 1 to 5; Preferably, the compound represented by formula (I) has the following structure: wherein A and ring G2 independently have the definitions of any one of claims 1 to 5; Preferably, the compound represented by formula (I) has the following structure: Among them, B, ring G2, X, Z, T, X1, X2, X3, R a , n, r, s, p, q independently have the definitions as described in any one of claims 1 to 5; Preferably, the compound represented by formula (I) has the following structure: wherein ring G2, X1, X2, and X3 independently have the definitions of any one of claims 1 to 5.
7. The compound according to any one of claims 1 to 6, characterized in that The compound is selected from the following structures:
8. A method for preparing the compound according to any one of claims 1 to 7, comprising the following steps: (1) Compound a reacts with compound A-NH2 to obtain compound b; (2) Compound b reacts with compound MH to obtain compound c; (3) Compound C reacts with compound EH to obtain a compound represented by formula (I); wherein A, E, M and ring G are independently defined as in any one of claims 1 to 7; L is selected from halogen, such as Cl, Br, I; and Q is selected from halogen, such as F, Cl, Br.
9. [Corrected 12.10.2023 in accordance with Rule 26] A pharmaceutical composition comprising a therapeutically effective amount of at least one of the compounds according to any one of claims 1 to 7, their racemates, stereoisomers, tautomers, isotopically labeled forms, solvates, polymorphs, pharmaceutically acceptable salts or prodrug compounds thereof.
10. Use of at least one of the compound according to any one of claims 1 to 7, its racemate, stereoisomer, tautomer, isotope-labeled form, solvate, polymorph, pharmaceutically acceptable salt, or prodrug thereof in the preparation of a medicament; Preferably, the use can be for the preparation of a medicament for treating KIF18A-mediated disorders and / or diseases, such as for the preparation of a KIF18A inhibitor drug; Preferably, the disease is cancer, such as colon cancer, breast cancer, lung cancer, pancreatic cancer, prostate cancer, bladder cancer, head and neck cancer, cervical cancer or ovarian cancer.
Citation Information
Patent Citations
KIF18a inhibitors
CN113226473A
KIF18A inhibitors
CN114269731A
Inhibitor of kinin KIF18A and application thereof
CN119278199A
Systems for computer network security risk assessment including user compromise analysis associated with a network of devices
US10044745B1
Systems for computer network security risk assessment including user compromise analysis associated with a network of devices
US20220053015A1
